

1 **Title:** Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid  
2 capture of fungi by macrophages

3

4 **Running title:** C3aR facilitates macrophage phagocytosis of fungi

5

6 Cohen, A.<sup>1</sup>, Jeng, E.E.<sup>2,3</sup>, Voorhies, M.<sup>1</sup>, Symington, J.<sup>1</sup>, Ali, N.<sup>1</sup>, Bassik, M.C.<sup>2</sup>, Sil, A.<sup>1</sup>

7 <sup>1</sup> University of California San Francisco, CA, Department of Microbiology and Immunology

8 <sup>2</sup> Stanford University, Palo Alto, CA, Department of Genetics

9 <sup>3</sup> Current address: AbbVie Inc, San Francisco, CA, Oncology Early Development

10

## 11 **Abstract**

12 The fungal pathogen *Histoplasma capsulatum* (*Hc*) invades, replicates within, and destroys  
13 macrophages. To interrogate the molecular mechanisms underlying this interaction, we  
14 conducted a host-directed CRISPR-Cas9 screen and identified 361 genes that modify  
15 macrophage susceptibility to *Hc* infection, greatly expanding our understanding of host gene  
16 networks targeted by *Hc*. We identified pathways that have not been previously implicated in  
17 *Hc* interaction with macrophages, including the ragulator complex (involved in nutrient stress  
18 sensing), glycosylation enzymes, protein degradation machinery, mitochondrial respiration  
19 genes, solute transporters, and the ER membrane complex (EMC). The highest scoring  
20 protective hits included the complement C3a receptor (C3aR), a G-protein coupled receptor  
21 (GPCR) that recognizes the complement fragment C3a. Although it is known that the  
22 complement system reacts with the fungal surface, leading to opsonization and release of  
23 small peptide fragments such as C3a, a role for C3aR in macrophage susceptibility to fungi  
24 has not been elucidated. We demonstrated that whereas C3aR is dispensable for macrophage  
25 phagocytosis of bacteria and latex beads, it is critical for optimal macrophage capture of  
26 pathogenic fungi, including *Hc*, the ubiquitous fungal pathogen *Candida albicans*, and the  
27 causative agent of Valley Fever *Coccidioides posadasii*. We showed that C3aR localizes to the  
28 early phagosome during *H. capsulatum* infection where it coordinates the formation of actin-  
29 rich membrane protrusions that promote *Hc* capture. We also showed that the EMC promotes  
30 surface expression of C3aR, likely explaining its identification in our screen. Taken together,  
31 our results provide new insight into host processes that affect *Hc*-macrophage interactions and  
32 uncover a novel and specific role for C3aR in macrophage recognition of fungi.

33

## 34 **Introduction**

35 *Histoplasma capsulatum* (*Hc*) is a fungal intracellular pathogen of macrophages.

36 Infection with *Hc* occurs when soil containing *Hc* spores or hyphal fragments is aerosolized  
37 and fungal particles are inhaled by a mammalian host (1). In the lung, *Hc* invades alveolar  
38 macrophages (2, 3), replicates to high intracellular levels and induces macrophage lysis (4, 5).  
39 Though many of the molecular mechanisms underpinning *Hc* pathogenesis are unknown, a  
40 number of *Hc* genes that promote immune evasion and virulence have been identified (6-10).

41 The initial step in *Hc*-macrophage interactions is phagocytosis. In general, macrophage-  
42 expressed pattern-recognition-receptors can directly bind common fungal cell-wall components  
43 (11) such as the cell-wall sugar  $\beta$ -glucan, which is recognized by the receptor Dectin-1 (12,  
44 13). Engagement of phagocytosis receptors, such as Dectin-1, triggers a complex cascade of  
45 intracellular signaling events, involving small GTPase activation, membrane phospholipid  
46 remodeling, and actin cytoskeleton polymerization that allow the plasma membrane to deform  
47 and encircle the targeted particle (14, 15). Following phagocytosis, the particle is enclosed  
48 within a membrane structure termed the phagosome. Macrophage phagocytosis of *Hc*, unlike  
49 that of other fungi, is not dependent on  $\beta$ -glucan recognition by Dectin-1 (16). *Hc* can prevent  
50 such recognition by shielding cell-wall  $\beta$ -glucan with a layer of  $\alpha$ -glucan (17) or by secreting  
51 glucanases to prune  $\beta$ -glucans (18). Instead, *Hc* recognition and phagocytosis is directly  
52 mediated by  $\beta$ 2 integrin receptors (16, 19) formed through dimerization of CD18 (*Itgb2*) with  
53 various  $\alpha$  subunits (20), such as CD11b, a subunit of complement receptor 3 (CR3).

54 Innate immune recognition of pathogens is supported by the complement system (21).  
55 Dozens of complement factors are secreted into biological fluids such as serum and  
56 bronchoalveolar fluid (22, 23), where they react with foreign particles and facilitate their  
57 destruction and recognition by innate immune cells (24). The complement cascade can be  
58 triggered by three main pathways: the antibody-dependent classical pathway; the lectin  
59 pathway, through recognition of microbial sugars; and the non-specific alternative pathway, all  
60 of which culminate in the cleavage and activation of C3 (21). Following C3 activation, C3b is  
61 covalently attached to the microbial surface, and is recognized by complement receptors (CRs)  
62 expressed on immune cells, which mediate phagocytosis (25). C3 cleavage also releases the  
63 small peptide fragment, C3a, which is recognized by the complement 3a receptor (C3aR), a G-  
64 protein coupled receptor (GPCR) which is expressed on innate immune cells (26). C3a acts as  
65 a chemoattractant for innate immune cells such as macrophages (27). C3aR can also  
66 modulate the production of cytokines in response to inflammatory stimuli (28), and has been  
67 implicated in the pathogenesis of diseases such as sepsis and allergic inflammation (29). C5 is  
68 activated downstream of C3, leading to the release of C5a, which is also a potent  
69 chemoattractant and inflammatory modifier through its interaction with its receptor, C5aR (29).  
70 While serum is a major source of complement, innate immune cells such as macrophages can  
71 also secrete complement components (30-32).

72 Ubiquitous opportunistic fungal pathogens, including *Candida albicans*, as well as  
73 endemic fungal pathogens such as *Coccidioides immitis* (33) and *Hc* (34), are strong activators  
74 of multiple serum complement pathways (35). Serum enhances the phagocytosis of  
75 opportunistic fungal pathogens, and the role of C3b/ inactivated C3b (iC3b) opsonization in

76 promoting uptake of fungi due to recognition by complement receptors is well-studied (35-38).  
77 In addition, complement plays an important role in host defense against opportunistic fungi,  
78 including *Candida albicans* (39) and *Cryptococcus neoformans* (40). Zymosan, a cell-wall  
79 preparation of *Saccharomyces cerevisiae*, is well-established as a model for complement  
80 activation (41). Additionally, CR3 can recognize glucans and is thought to promote  
81 complement-independent recognition of *Hc* (16, 19, 25). C5a-C5aR signaling can also promote  
82 neutrophil migration towards and phagocytosis of *Cryptococcus neoformans* (42) and promote  
83 monocyte cytokine production in response to *Candida albicans* infection (43). However, the  
84 role of complement in innate immune recognition of *Hc* and of C3a-C3aR signaling in  
85 macrophage interaction with fungi has not been investigated.

86 To characterize host genes that underlie macrophage susceptibility to infection with *Hc*,  
87 we took advantage of a powerful pooled host-side screening platform (44) that has been  
88 successfully employed to identify host targets of intracellular pathogens (45, 46) and microbial  
89 toxins (47). We screened a CRISPR-Cas9 knockout library in macrophage-like cells  
90 challenged with *Hc*, and identified genes required for macrophage susceptibility to *Hc*-  
91 mediated lysis. We identified a number of host pathways that affected macrophage  
92 susceptibility to *Hc* infection, and focused our studies on molecules that influence *Hc*  
93 phagocytosis. This led to the discovery that C3aR and GPCR signaling plays an important role  
94 in promoting serum-dependent phagocytosis of *Hc* and other fungi. In addition, our screen  
95 identified the ER membrane (EMC) complex subunit Emc1, which we discovered is critical for  
96 surface expression of C3aR but not integrin receptors. This finding suggests a role for the  
97 EMC, which facilitates folding of transmembrane helices in the ER, in the biogenesis of

98 GPCRs in innate immune cells. Overall our findings shed light on molecular mechanisms  
99 underlying innate immune recognition of fungi, and uncover new host pathways that may be  
100 targeted by *Hc* to promote virulence.

## 101 **Results**

### 102 **A large-scale pooled CRISPR screen in J774A.1 macrophage-like cells identified genes** 103 **required for macrophage susceptibility to infection with *H. capsulatum***

104 To identify genes that affect macrophage sensitivity to parasitization by *Hc*, we  
105 conducted pooled CRISPR-Cas9 knockout screens in the J774A.1 mouse macrophage-like  
106 cell-line (Fig. 1). This cell line has been widely used to model macrophage interactions with  
107 pathogenic microbes, including *Hc* (7, 9). We demonstrated that *Hc* can induce lysis of  
108 J774A.1 cells in a manner dependent on the secreted effector Cbp1 (Fig. S1A), which is  
109 consistent with studies in primary macrophages (7, 9, 10).

110 To create our knockout libraries, we first generated a clonal J774A.1 cell-line with high  
111 constitutive Cas9 activity (Fig. S1B). We then transduced these Cas9-expressing J774A.1 cells  
112 with pooled lentiviral sgRNAs. We used a previously designed CRISPR-Cas9 sgRNA library,  
113 which targets 23,000 protein-coding mouse genes with 10 sgRNAs/gene. The genome-wide  
114 library is split into 20 sub-libraries, each of which covers 500-1500 genes and includes 750  
115 negative control sgRNAs (48). We screened each sub-library separately, covering a total of  
116 16,782 genes. These cells were infected, in duplicate, with *Hc*, or were left uninfected and  
117 passaged throughout the course of the screen (Fig. 1A). To improve the sensitivity of our  
118 screen, we used a strain of *Hc* with a mutation in the *URA5* gene (*Hc ura5Δ*) which cannot  
119 grow in media without uracil supplementation (49). This strain does not lyse J774A.1 cells in

120 the absence of exogenous uracil, and host cells that survive the initial round of lysis can be  
121 recovered by washing the monolayer and incubating in media without uracil supplementation  
122 (Fig. S1C-E), thereby allowing enrichment of resistant host cells. We infected the J774A.1  
123 pools with *Hc ura5Δ* and performed 2-3 rounds of *Hc*-mediated lysis in the presence of uracil  
124 followed by uracil removal and recovery (see table S2 for sub-library specific details). We  
125 pulsed the uninfected cells with uracil during passaging to match the *Hc* infection. The sgRNAs  
126 in the final pools were deep-sequenced to determine the enrichment of guides following  
127 challenge with *Hc*. We employed the Cas9 high-throughput maximum-likelihood estimator  
128 (casTLE) algorithm (50) to estimate the effect of knocking out a gene on susceptibility to *Hc*  
129 (caSTLE effect) based on the enrichment of guides targeting each gene in the screen  
130 compared to the enrichment of negative control sgRNAs. We additionally analyzed uninfected  
131 cells at the beginning and the end of passaging using the casTLE algorithm, and we were able  
132 to verify that guides targeting genes previously annotated as essential (50) dropped out of the  
133 pool during passaging (Fig. S1H).

134 We identified 361 genes whose deletion modulated macrophage susceptibility to *Hc*  
135 infection at a 5% false-discovery rate (Fig. 1B). Confidence scores between screen replicates  
136 were moderately correlated (Fig. S1F). Disruption of 322 of these genes conferred protection  
137 against *Hc* (combo casTLE effect >0), and disruption of 39 conferred greater susceptibility to  
138 infection (combo casTLE effect <0) (Fig. 1B). We noticed that the protective hits include genes  
139 known to be required for macrophage phagocytosis, such as members of the SCAR/WAVE  
140 and ARP2/3 complexes (Fig. 1C-D). Such regulators have been well-studied for their role in  
141 phagocytosis and chemotaxis (14, 51, 52). Similarly, we identified *Itgb2* (CD18), which

142 encodes the  $\beta$ -subunit of CR3 that has been previously shown to facilitate recognition and  
143 phagocytosis of *Hc* (16, 19), and *Fermt3*, which promotes activation of integrins (53) (Fig. 1D).

144 Of note, we identified a number of pathways and complexes among the resistance-  
145 promoting hits that have not been previously implicated in *Hc* interaction with macrophages  
146 (Fig. 1D), such as the ragulator complex, glycosylation enzymes, protein degradation  
147 machinery, mitochondrial respiration genes, solute transporters, and the ER membrane  
148 complex (EMC). The ragulator complex promotes nutrient stress sensing (54), and the EMC  
149 facilitates the folding of transmembrane proteins with multiple membrane-spanning regions  
150 (55, 56). The highest scoring protective hits include a group of genes (*Gnb2*, *Pdcl*, AP-1  
151 subunits, AP-2 subunits, *Arrb2*) that regulate G-protein coupled receptor (GPCR) signaling and  
152 receptor trafficking following GPCR engagement (Fig. 1D) (57, 58). The hit identified with the  
153 second-highest confidence score was the gene encoding the GPCR C3a receptor 1  
154 (*C3ar1/C3aR*) (Fig. 1D). Histograms demonstrating the enrichment of negative control sgRNAs  
155 and sgRNAs targeting *Gnb2* and *C3ar* in the *Hc*-infected pool are shown in Fig. S1G. We went  
156 on to investigate whether these factors play a role in macrophage phagocytosis of *Hc*.

157

### 158 **Identification of genes required for phagocytosis of yeast in J774A.1 macrophage-like** 159 **cells and primary macrophages**

160 We selected 16 high-confidence hits to individually validate in J774A.1 macrophage-like  
161 cells, including two genes, SCAR/WAVE subunit *Nckap1l*, and *Itgb2*, which were expected to  
162 play a role in macrophage phagocytosis of *Hc*. We prioritized genes that would shed light on  
163 novel aspects of macrophage interactions with *Hc* and that did not appear to strongly inhibit



164 macrophage replication. We chose the three top-performing guides, based on enrichment or  
165 depletion in the screen, for further validation.

166 To verify susceptibility/resistance phenotypes in J774A.1 cells, we mixed GFP+,  
167 CRISPR-knockout (KO) cells with Cas9-expressing unlabeled cells, infected one pool of this  
168 mixture with *Hc*, and in parallel passaged the uninfected pool. Following one round of lysis and  
169 recovery, the pools were then harvested, and the proportion of GFP-expressing cells was  
170 measured via flow cytometry (Fig. 2A). The ratio of GFP+ cells in the *Hc*-infected compared to  
171 the uninfected pool demonstrated whether targeting a specific gene conferred a fitness  
172 advantage (>1) or disadvantage (<1) to macrophages during co-culture with *Hc*. Of the 16  
173 genes tested, 13 conferred a fitness advantage during *Hc* infection when disrupted, including  
174 *Gnb2*, *C3ar*, ER membrane complex subunits *Emc1*, *Emc6*, and *Emc7*, and ubiquitin ligase  
175 *Ubr5* (Fig. 2B). As positive controls, we included knockouts of SCAR/WAVE subunit *Nckap1l*,  
176 and the  $\beta$ -2 integrin subunit of CR3, *Itgb2* (Fig. 2B). The only susceptibility-promoting hit that  
177 we tested, *Rab21*, did not promote increased susceptibility to *Hc* infection when disrupted (Fig.  
178 2B).

179 Next, we tested whether these genes play a role in macrophage phagocytosis of *Hc*  
180 yeast. To this end, we mixed GFP+, CRISPR-targeted cells with unlabeled, Cas9-expressing  
181 cells, infected the mixture with mCherry-expressing *Hc* yeast, and stained the cells with  
182 calcofluor white (CFW) to distinguish between intracellular and extracellular yeast. We used  
183 flow cytometry to measure the representation of GFP+ cells in the phagocytic compared to the  
184 non-phagocytic population (Fig. 2C). As expected, targeting of *Nckap1l*, *Fermt3*, and *Itgb2* led

185 to decreased *Hc* phagocytosis in J774A.1 cells (Fig. 2D). Additionally, we found that knockout  
186 of *Emc1*, *Gnb2*, *C3ar1*, and *Arrb2* decreased phagocytosis of *Hc* (Fig. 2D).

187 Although J774A.1 cells recapitulate many important features of primary macrophages,  
188 including phagocytosis, they also differ in characteristics such as gene expression regulation  
189 (59). Therefore, we attempted to reproduce our findings from J774A.1 cells in bone marrow-  
190 derived macrophages (BMDMs) using CRISPR-Cas9-mediated gene disruption. We mixed  
191 CRISPR-knockout, Thy1.1+ BMDMs with WT, unlabeled BMDMs, infected the mixture with *Hc*  
192 yeast, and assessed phagocytosis as described above. We quantified the proportion of  
193 Thy1.1+ cells in the phagocytic compared to the non-phagocytic populations to determine  
194 whether the targeted genes promoted BMDM phagocytosis of *Hc* yeast. The four genes that  
195 we tested, GPCR *C3ar1*, integrin subunit *Itgb2*, ER membrane complex *Emc1*, and G $\beta$  subunit  
196 *Gnb2*, were also required for efficient phagocytosis of *Hc* yeast by BMDMs (Fig. 2E).

197

### 198 **C3aR signaling plays a role in macrophage phagocytosis of fungi**

199 Since a role for C3aR in phagocytosis of fungi had not previously been defined, we  
200 were intrigued by the result that this receptor is required for efficient phagocytosis of *Hc* by  
201 J774.1 cells and BMDMs. C3aR is a GPCR that recognizes the complement C3 cleavage  
202 product, anaphylatoxin C3a, and signals through G $\alpha$ i (29), which is sensitive to pertussis toxin-  
203 mediated ADP-ribosylation (60). We further investigated the role of C3aR and GPCR signaling  
204 in macrophage phagocytosis of fungi. We generated BMDMs from *C3ar1*<sup>-/-</sup> mice (61) and age-  
205 matched WT mice. We then infected these macrophages with several species of pathogenic  
206 fungi including *Hc* yeast expressing mCherry (Fig. 3A-B, G-I), *Candida albicans* (*Ca*) yeast

207 detected with a fluorescent antibody (Fig. 3C), and *Coccidioides posadasii* arthroconidia  
208 labeled with FITC (*Cp*) (Fig. 3D), and determined the extent of phagocytosis over time. We  
209 also tested phagocytosis of FITC-labeled zymosan (Fig. 3B), a cell-wall extract of  
210 *Saccharomyces cerevisiae*. We used calcofluor white staining to distinguish between  
211 intracellular and extracellular fungi. We observed that C3aR was required for efficient  
212 phagocytosis of all three species of fungal pathogens, in addition to zymosan, suggesting an  
213 important general role for C3aR in macrophage capture and phagocytosis of fungi (Fig. 3A-D).  
214 The involvement of C3aR did not require fungal viability, as C3aR was equally important for  
215 phagocytosis of both live and killed *Hc* yeast, as well as zymosan (Fig. 3A-B). The  
216 phagocytosis defect was not due to a defect in CD11b or CD18 surface expression in *C3ar*<sup>-/-</sup>  
217 BMDMs (Fig. S2).

218 C3aR has been previously implicated in macrophage uptake of certain, though not all,  
219 bacterial pathogens (62, 63), and in microglial phagocytosis of several substrates (64-66). To  
220 investigate whether the requirement of C3aR for phagocytosis extends to other types of  
221 particles that can be taken up by macrophages, we measured the capture of uncoated latex  
222 beads and FITC-labelled *E. coli* K12 in WT and *C3ar*<sup>-/-</sup> BMDMs (Fig. 3E-F). We found that  
223 C3aR was not required for uptake of *E. coli* (Fig. 3E) or latex beads (Fig. 3F), suggesting that  
224 C3aR does not play a general role in phagocytosis.

225 To further validate the contribution of C3aR to phagocytosis, we treated macrophages  
226 with a specific non-peptide antagonist of C3aR, SB290157 (67) five minutes before challenge  
227 with *Hc* (Fig. 3G). We found that the C3aR antagonist was able to inhibit macrophage  
228 phagocytosis of *Hc*, suggesting an acute role for C3aR in macrophage phagocytosis of fungi.

229 C3aR signaling is dependent on pertussis toxin-sensitive  $G_{\alpha i}$  (29), inhibition of which interferes  
230 with macrophage phagocytosis of Zymosan particles (68). We assessed whether  $G_{\alpha i}$  inhibition  
231 by pre-treatment of macrophages with pertussis toxin (Ptx) would impact macrophage  
232 phagocytosis of *Hc* yeast, and whether Ptx treatment would synergize with C3aR deficiency.  
233 We found that Ptx pre-treatment inhibited macrophage phagocytosis of *Hc* (Fig. 3H). Ptx  
234 treatment strongly phenocopies the phagocytosis defect in *C3ar*<sup>-/-</sup> BMDMs, and Ptx treatment  
235 modestly inhibits phagocytosis in *C3ar*<sup>-/-</sup> BMDMs (Fig. 3H). These findings show that C3aR-  
236 dependent  $G_{\alpha i}$  activation promotes phagocytosis, although  $G_{\alpha i}$  activation by other receptors,  
237 and C3aR coupling to a different  $G_{\alpha}$  subunit, may play a minor role in *Hc* phagocytosis (Fig.  
238 3H). We also investigated whether C3aR interacts with CR3 to promote phagocytosis by  
239 treating BMDMs with a CD18 blocking antibody (GAME-46) previously used to block CR3(16)  
240 (Fig. 3I). WT BMDMs treated with the CD18 inhibitor had a modest defect in phagocytosis of  
241 *Hc*, and treatment of *C3ar*<sup>-/-</sup> BMDMs with the inhibitor did not further block phagocytosis of *Hc*,  
242 suggesting that CR3 participates in phagocytosis downstream of C3aR (Fig. 3I).

243 We further reasoned that *Emc1* may indirectly promote phagocytosis due to its role in  
244 stabilization of proteins with multiple transmembrane helices (56), such as C3aR. To test this  
245 hypothesis, we measured C3aR expression in *Emc1* CRISPRKO BMDMs (Fig. 3J-L). We saw  
246 a dramatic decrease in C3aR expression in *Emc1*-targeted BMDMs compared to untransduced  
247 or control-targeted BMDMs (Fig. 3J-L), suggesting that the EMC facilitates the proper folding  
248 and biosynthesis of GPCRs, such as C3aR, in macrophages. In contrast, *Emc1* CRISPRKO  
249 BMDMs did not show reduced surface expression of CD18 or CD11b (Fig. S2), verifying that

250 the EMC may not be as critical for proper folding of single-pass transmembrane proteins like  
251 integrins.

252 Since phagocytosis of *Hc* is delayed in *C3ar*<sup>-/-</sup> BMDMs, we expected lysis of infected  
253 BMDMs to show a corresponding delay. As expected, we found that *C3ar*<sup>-/-</sup> BMDMs were  
254 slightly less susceptible to *Hc*-mediated lysis, as measured by an established assay (9, 69)  
255 (Fig. S3). Analysis of *Hc* colony forming units (CFUs) indicated that *C3ar*<sup>-/-</sup> macrophages were  
256 infected with fewer *Hc* yeast at the start of the experiment, and *Hc* yeasts did not have a major  
257 intracellular growth defect in the mutant macrophages (Fig. S3). We did not observe a  
258 difference in *Hc*-induced TNF $\alpha$  secretion in the absence of C3aR, suggesting that C3aR does  
259 not affect macrophage cytokine release in response to *Hc* (Fig. S4).

260

### 261 **Serum C3 promotes complement opsonization and macrophage phagocytosis of *Hc*** 262 **yeast**

263 Since the canonical ligand for C3aR is C3a derived from C3 processing, we investigated  
264 whether serum represented a source of C3 that would react with *Hc* to generate C3a and  
265 promote phagocytosis. Macrophage infections discussed up to this point were conducted in the  
266 presence of 10% (for J774A.1 cells) or 20% (for BMDMs) heat-inactivated fetal bovine serum  
267 (FBS), which was not previously thought to be a robust source of complement.

268 We infected WT and *C3ar*<sup>-/-</sup> BMDMs with mCherry<sup>+</sup> *Hc* and FITC-labelled zymosan in  
269 the presence or absence of 20% heat-inactivated FBS, and monitored phagocytosis by flow  
270 cytometry. Surprisingly, we found that FBS promoted macrophage phagocytosis of *Hc*, and to  
271 a lesser extent zymosan, in a C3aR-dependent manner (Fig. 4A). Even after 2h of co-culture,

272 we did not observe efficient phagocytosis of *Hc* by BMDMs in serum-free media (Fig. 4B).  
273 Phagocytosis of zymosan by BMDMs in serum-free media was more efficient than that of *Hc*,  
274 and was not dependent on C3aR (Fig. 4A), as expected due to the role of Dectin 1-mediated  
275 recognition of  $\beta$ -glucans in non-opsonic macrophage recognition of zymosan (38). The low  
276 level of *Hc* phagocytosis in serum-free media was also C3aR-independent. The ability of FBS  
277 to stimulate phagocytosis is not lot-dependent, as FBS from different lots and manufacturers  
278 promoted macrophage phagocytosis of *Hc* in a C3aR-dependent manner (Fig. S5). To assess  
279 whether FBS was promoting phagocytosis by opsonization of the yeast, we tested whether  
280 pre-incubation with FBS would be sufficient to stimulate phagocytosis of *Hc* in serum-free  
281 media (Fig. 4B). We found that pre-incubation in FBS did not promote phagocytosis of *Hc* or  
282 zymosan (Fig. 4B), suggesting either that FBS does not facilitate phagocytosis by  
283 opsonization, or that opsonization is labile. We also determined that incubating *Hc* with BMDM  
284 conditioned media containing FBS did not promote macrophage phagocytosis of *Hc* (Fig.  
285 S6B), suggesting that BMDMs do not secrete a missing factor that would restore FBS-  
286 mediated opsonization of *Hc*.

287 To establish a role for serum-derived C3 in macrophage recognition of *Hc*, we  
288 compared phagocytosis of *Hc* in media supplemented with no serum, FBS, or serum collected  
289 from WT or *C3*<sup>-/-</sup> C57BL/6 mice (WT NMS or *C3*<sup>-/-</sup> NMS) (Fig. 4C). We found that mouse  
290 serum promoted macrophage phagocytosis of *Hc* in a C3-dependent manner that was  
291 sensitive to heat inactivation (Fig. 4C). Surprisingly, the ability of mouse serum to stimulate  
292 phagocytosis of *Hc* was not dependent on C3aR (Fig. 4C), suggesting an additional C3aR-  
293 independent, C3-dependent mechanism of phagocytosis. Since C5 can be activated

294 downstream of C3, leading to the release of the potent chemoattractant C5a (21), we reasoned  
295 that serum from C57BL/6 mice might stimulate phagocytosis via C5. C5a release and  
296 recognition by C5aR would then stimulate phagocytosis and compensate for C3aR-deficiency.  
297 To test this, we supplemented the media with serum from DBA2 mice, which have low levels of  
298 serum C5, but normal levels of C3 (70). We found that *C3ar*<sup>-/-</sup> BMDMs were defective at  
299 phagocytosis of *Hc* in media supplemented with DBA2 (C5-deficient), but not C57BL/6 (C5-  
300 sufficient) serum (Fig. 4D), suggesting that C5a in C57BL/6 serum acts redundantly with C3a  
301 to promote macrophage phagocytosis of *Hc*.

302 To confirm that incubating mouse serum with *Hc* yeast would promote opsonization with  
303 C3, as previously described (71), and C3a release, we incubated *Hc* yeast and zymosan  
304 (positive control) with mouse serum, visualized C3 deposition using immunofluorescence  
305 confocal microscopy (Fig. 4E-F) and measured C3a levels in the supernatant by ELISA (Fig.  
306 4G). We observed robust C3 staining of *Hc* upon incubation with WT serum, and no C3  
307 deposition after incubation with *C3*<sup>-/-</sup> sera (Fig. 4E). We also found that incubating WT  
308 C57BL/6 and DBA2 serum with *Hc* increased C3a levels in the supernatant (Fig. 4G),  
309 suggesting C3a release. To inhibit the classical/lectin pathways, or all activation pathways, we  
310 added EGTA or EDTA, respectively, to the indicated reactions. We did not observe C3  
311 deposition or C3a release when Mg<sup>++</sup> was chelated with EDTA (Fig. 4E). We also saw C3  
312 deposition, although with lower efficiency and with a less uniform distribution around the yeast  
313 cell-wall, and lower levels of C3a release, in the presence of EGTA (Fig. 4E-G). These results  
314 confirm that *Hc* can activate the alternative complement pathway, as previously suggested  
315 (34). Due to the increased efficiency and uniformity of C3 deposition on yeast and the

316 increased C3a release found in the absence of EGTA, we suggest that the classical or lectin  
317 pathways also contribute to C3 opsonization of *Hc* yeast. We did not find evidence of C3  
318 deposition on the cell-surface following incubation of *Hc* with FBS or BMDM conditioned media  
319 containing FBS (Fig. S6A). To demonstrate that complement opsonization by mouse serum  
320 promotes macrophage phagocytosis of *Hc* yeast, we infected BMDMs in serum-free media  
321 with *Hc* opsonized by WT or *C3*<sup>-/-</sup> mouse serum. We found that opsonization with WT mouse  
322 serum, but not *C3*<sup>-/-</sup> serum, is sufficient to promote phagocytosis of *Hc* in serum-free media in  
323 a C3aR-independent manner, suggesting direct recognition of opsonized yeasts by CR3 (Fig.  
324 4C). This activity was blocked by EDTA and moderately inhibited by EGTA, suggesting  
325 contribution of both the classical/lectin and alternative pathways to phagocytosis stimulation  
326 through opsonization (Fig. S6B).

327 Active complement C3 can also be secreted by macrophages (30-32). We measured  
328 the release of C3 into culture supernatants by ELISA, and found that *Hc* infection did stimulate  
329 a modest macrophage secretion of C3 (Fig. S7A). However, we did not observe a  
330 phagocytosis defect when we infected *C3*<sup>-/-</sup> BMDMs with *Hc* or zymosan in the presence of  
331 FBS (Fig. S7B), suggesting that macrophage-derived C3 is not playing a major role in  
332 macrophage phagocytosis of *Hc* in our assay.

333

### 334 **C3aR localizes to the early *Hc*-containing phagosome**

335 We next analyzed C3aR localization during macrophage phagocytosis of *Hc* and latex  
336 beads, whose uptake does not depend on C3aR. These experiments were conducted in media  
337 supplemented with 20% FBS. Localization to the *Hc* containing phagosome would implicate



338 C3aR directly in fungal capture or phagocytic cup formation. Immunofluorescence confocal  
339 microscopy confirmed that C3aR is localized at the plasma membrane (Fig. S8). We observed  
340 C3aR localization to the *Hc*-containing phagosomes at 5- and 10-minutes post-infection, and  
341 with a lower frequency at 30 minutes post-infection (Fig. 5A). Examples of C3aR-positive  
342 phagosomes are indicated by white arrows in the images. In contrast, we did not observe  
343 C3aR-positive bead-containing phagosomes at the same frequency (Fig. 5B), suggesting that  
344 C3aR localizes specifically to the *Hc*-containing phagosome, and not to latex bead-containing  
345 phagosomes.

346 To quantify C3aR localization to the *Hc* or bead-containing phagosome, we used  
347 imageJ to measure the mean intensity over background of the C3aR signal surrounding the *Hc*  
348 or bead particle. Our analysis revealed that *Hc*-containing phagosomes display significantly  
349 higher C3aR enrichment than bead-containing phagosomes (T-test, P-value <0.05) at 5- and  
350 10-minutes post-infection, but not at 30 minutes post-infection as the phagosomes mature (Fig.  
351 5C).

352

### 353 **C3aR promotes the formation of actin-rich protrusions that facilitate capture of *Hc* yeast**

354 Since C3a is a chemoattractant for macrophages, we investigated the role of  
355 macrophage migration in the C3aR-dependent capture of *Hc* yeast. Although macrophages did  
356 undergo chemotaxis towards *Hc* in trans-well migration assays, migration was not dependent  
357 on FBS or C3aR (Fig. S9). We also were not able to rescue the phagocytosis of *Hc* by *C3ar*<sup>-/-</sup>  
358 macrophages when the likelihood of *Hc*-macrophage interaction was increased by  
359 centrifugation of *Hc* onto the monolayer, or an extended pre-incubation on ice (Fig. S10).

360 These experiments suggest that C3aR involvement in macrophage phagocytosis of *Hc* is not  
361 due to its role in facilitating long-range migration of macrophages towards yeast. However,  
362 these studies do not rule out a role for C3aR-dependent control of short-range chemotaxis in  
363 macrophage capture of *Hc* yeast.

364 To investigate this possibility, we generated J774A.1 cells that express Lifeact-mEGFP,  
365 a probe that specifically labels F-actin (72), and performed live imaging of J774A.1  
366 macrophages during co-culture with mCherry-labelled yeast in the presence of a C3aR  
367 antagonist (SB290157) or a vehicle control using confocal microscopy (Fig. 6). These movies  
368 show macrophages extending actin-rich membrane protrusions in the direction of nearby *Hc*  
369 that promote rapid *Hc* capture and engulfment (example time series shown in Fig. 6A). In  
370 contrast, C3aR antagonist-treated macrophages show much slower capture of *Hc* yeast, and  
371 fail to rapidly form such actin-rich directed membrane protrusions (Fig. 6B). Membrane  
372 protrusions of macrophages that eventually capture *Hc* yeast were tracked and analyzed (73)  
373 (Fig. 6C-E). Treatment with the C3aR antagonist dramatically slowed capture of *Hc* yeast, as  
374 demonstrated by the lower phagocytosis rate and the lower mean velocity of the tracked  
375 protrusions (Fig. 6D). Finally, the movement of the antagonist-treated membrane protrusions  
376 was less directional, as demonstrated by the lower outreach ratio of the membrane protrusions  
377 (Fig. 6E).

378 Live imaging experiments showed that C3aR facilitates the directional movement of  
379 actin-rich membrane protrusions towards *Hc* yeast that facilitate rapid phagocytosis. This  
380 behavior likely requires a C3a gradient that diffuses away from the *Hc* yeast following  
381 complement cleavage at the fungal surface. Consistent with this idea, the addition of

382 recombinant C3a to BMDMs in the absence of a gradient was not sufficient to stimulate  
383 macrophage phagocytosis of *Hc* in serum-free media (Fig. S11).

384

## 385 **Discussion**

386 We report a large-scale CRISPR-Cas9 screen conducted in macrophage-like cells  
387 challenged with *Hc* yeast. 361 genes emerged as high-confidence modifiers of macrophage  
388 susceptibility to *Hc*-mediated killing, vastly expanding our knowledge of the gene networks that  
389 underpin macrophage interaction with this important pathogen. Validation of top hits revealed  
390 an under-appreciated role for GPCR signaling through C3aR in macrophage phagocytosis of  
391 fungi. These results are particularly intriguing for *Histoplasma*, which is an intracellular fungal  
392 pathogen that thrives within the macrophage phagosome. Therefore, elucidating the molecular  
393 events that govern *Histoplasma* phagocytosis is particularly important for understanding *Hc*  
394 pathogenesis. Given that C3aR strongly enhances the efficiency of *Hc* phagocytosis, it may be  
395 a key host factor that promotes the intracellular lifestyle of this organism.

396 It was previously established that macrophage phagocytosis of *Hc* is not dependent on  
397  $\beta$ -glucan recognition by Dectin-1 (16), and that *Hc* utilizes a number of mechanisms to  
398 minimize exposure of  $\beta$ -glucan on the cell surface (17, 18). In contrast, CR3 has been  
399 previously implicated in non-opsonic uptake of *Hc* (16, 19). Our work uncovers the important  
400 role of C3aR as a pattern recognition receptor for *Hc* and other fungi, potentially collaborating  
401 with CR3 to facilitate uptake of pathogenic yeasts that shield  $\beta$ -glucan from recognition by  
402 Dectin-1 (described in Fig. 7). We also discovered that C3aR-dependent phagocytosis requires  
403 serum, and that only mouse serum that was replete with C3 could stimulate phagocytosis,

404 suggesting that a gradient of C3a emanating from the fungal surface might be critical for the  
405 phagocytic activity of C3aR as discussed below. Since *Hc* cannot engage Dectin-1, there is  
406 little phagocytosis of *Hc* in the absence of serum. In contrast, the residual serum-independent,  
407 C3aR-independent phagocytosis of zymosan may be due to Dectin-1. Given that *Hc* is  
408 introduced to the host via inhalation, and since complement activity is present in the  
409 bronchoalveolar fluid (22, 23), innate immune recognition of *Hc* likely occurs in the context of  
410 complement activation *in vivo*.

411 The vast majority of genes identified in the screen were resistance-promoting hits,  
412 which may reflect limitations in the pooled screening approach, or the efficiency at which *Hc*  
413 evades macrophage defenses (in other words, it is challenging to increase macrophage  
414 sensitivity to *Hc*). Within these hits, we identified genes with previously described involvement  
415 in phagocytosis and *Hc* recognition, which validates our approach and is consistent with the  
416 requirement for *Hc* uptake to trigger the process of macrophage lysis. Our screen also  
417 revealed a role for GPCR signaling in *Hc*-host interactions. In addition to *C3ar*, the highest  
418 scoring protective hits included a set of genes that regulate signaling and receptor trafficking  
419 following GPCR engagement (57, 58). We validated that several of these genes, including  
420 *C3ar1*, *Gnb2*, and *Arrb2*, facilitate macrophage phagocytosis of *Hc*. While G-protein coupled  
421 receptor (GPCR) signaling is traditionally thought to play a role in chemotaxis rather than  
422 phagocytosis (74, 75), several studies have implicated G-protein activity directly in  
423 cytoskeleton coordination during phagocytosis (68, 76, 77). Both chemotaxis and phagocytosis  
424 depend on precise regulation of the actin cytoskeleton, and signaling often converges on the  
425 same signaling cytoskeleton remodeling machinery (74). Additionally, previous studies have

426 shown that the mobility and activity of phagocytosis receptors is increased at the leading edge  
427 of a cell (78), and that active probing of the local environment by macrophages is critical for  
428 efficient binding of targets (79), suggesting strong coordination between chemotaxis and  
429 phagocytosis. We also identify the ER membrane complex, which facilitates the folding of  
430 transmembrane proteins with multiple membrane-spanning regions (55, 56). We show that  
431 *Emc1* promotes macrophage phagocytosis of *Hc*, and is required for surface expression of  
432 C3aR, but not CR3 subunits. Thus, we propose that the EMC indirectly participates in  
433 phagocytosis due to its role in folding receptors such as C3aR.

434 Other genes and complexes identified in this screen may play important roles in *Hc*  
435 interaction with macrophages. To uncover the nature of their involvement will require further  
436 study. These include the ragulator complex, which activates mTORC1 upon nutrient  
437 deprivation and regulates autophagic flux that can be critical for defense against intracellular  
438 pathogens (54). This complex also has been found in screens for phagocytosis regulators (51),  
439 and has been shown to modulate phagocytic flux in microglia (80). Other hits may affect *Hc*-  
440 macrophage interactions through indirect means, or promote nutrient acquisition and  
441 intracellular replication within the phagosome. We also identified ubiquitin ligases such as *Ubr5*  
442 and *Trip12*, which regulate histone ubiquitylation upon DNA damage (81). *Ubr5* has also been  
443 shown to down-regulate TLR signaling (82). Validation in macrophage-like cells demonstrates  
444 that *Ubr5* is required for *Hc*-induced lysis, but not macrophage phagocytosis of *Hc*, suggesting  
445 that *Ubr5* promotes intracellular replication of *Hc* or macrophage cell-death.

446 Since the identification of C3aR as a phagocytic receptor was intriguing, we further  
447 characterized its role in macrophage phagocytosis of *Hc* and other targets. While we found

448 that C3aR was required for phagocytosis of several species of fungi, C3aR did not play a  
449 general role in phagocytosis, as *C3ar*<sup>-/-</sup> macrophages were not defective in uptake of *E. coli* or  
450 latex beads. Previous studies have demonstrated that C3aR promotes phagocytosis of  
451 damaged neurons (83), myelin particles (66) and protein aggregates (64). C3aR has also been  
452 implicated in macrophage phagocytosis of uropathogenic *E. coli* (63), but not *Pseudomonas*  
453 *aeruginosa* (62). Further study is needed to determine the shared characteristics of particles  
454 that require C3aR for optimal phagocytosis, such as particle size, reactivity with complement,  
455 or other biochemical properties. Nonetheless, the identification of C3aR as an important  
456 phagocytic receptor for fungi implies that it may play a critical role in host defense to fungal  
457 pathogens. More study is needed to determine whether C3aR affects host susceptibility to  
458 fungal pathogens or modulates the immune response to fungi. Such study will be essential to  
459 determining the therapeutic benefit of targeting complement or C3aR in the treatment of  
460 invasive fungal infections.

461 We found that heat-inactivated fetal bovine serum (FBS) added to the macrophage  
462 media promoted fungal phagocytosis in C3ar-dependent but opsonization-independent  
463 manner. This suggests that FBS promotes phagocytosis predominantly by generating C3a that  
464 activates C3aR, although the mechanism by which FBS-derived C3a might play a role  
465 independent of C3b opsonization is unclear. We also showed that mouse serum was able to  
466 stimulate macrophage phagocytosis of *Hc* in a C3-dependent manner, and that C3  
467 opsonization of *Hc* promoted macrophage phagocytosis, consistent with studies showing a role  
468 for C3b/C3bi in recognition of fungal pathogens (35). Surprisingly, the ability of serum from  
469 C57BL/6 mice to promote macrophage phagocytosis of *Hc* was not dependent on C3aR. We

470 demonstrated that C5a-C5aR signaling compensated for C3aR deficiency, since macrophage  
471 phagocytosis of *Hc* in the presence of serum from DBA2 mice, which are C5-deficient, was  
472 dependent on C3aR. This is not surprising given that C5a and C5aR have been previously  
473 implicated in innate immune recognition of fungi (42, 43, 84).

474 To investigate the role of C3aR in macrophage phagocytosis of *Hc*, we demonstrated  
475 that C3aR localizes to the *Hc* containing phagosome at early time-points during infection.  
476 Localization of C3aR to the phagosome suggests direct involvement of C3aR in *Hc* recognition  
477 or cytoskeleton remodeling. Alternatively, C3aR might not directly participate in phagosome  
478 formation, but display enrichment at the plasma membrane sites that participate in *Hc*  
479 phagocytosis.

480 Finally, live imaging of actin dynamics in macrophages during *Hc* infection revealed that  
481 C3aR promotes the directional movement of actin-rich membrane protrusions that aid in the  
482 capture of *Hc* yeast. This is consistent with the ability of C3a to promote chemotaxis of innate  
483 immune cells including macrophages (27), and the role of G-protein signaling in activating  
484 cytoskeleton remodeling at the leading edge and the phagocytic cup (68, 76, 77). We did not  
485 find strong evidence that C3aR promotes chemotaxis towards *Hc* yeast in trans-well assays,  
486 and we were not able to restore phagocytosis in *C3ar*<sup>-/-</sup> macrophages by forcing contact  
487 between macrophages and *Hc*, suggesting that C3aR participates in short-distance rather than  
488 long-distance migration during fungal phagocytosis. C3aR may also promote optimal  
489 phagocytosis by spatially coordinating receptor mobility (78) or activation (58) at the leading  
490 edge. We believe that a gradient of C3a diffusing away from the *Hc* surface is critical this  
491 activity, as the uniform distribution of recombinant C3a alone was not sufficient to stimulate

492 macrophage phagocytosis in the absence of serum. More investigation is needed to untangle  
493 the precise mechanism by which the C3a-C3aR pathway contributes to *Hc* recognition.

## 494 **Materials and Methods**

### 495 **Strains and culture conditions**

496 J774A.1 cells (ATCC) were cultured in Dulbecco's modified Eagle's medium high  
497 glucose (DMEM, UCSF media production) with 10% heat-inactivated fetal bovine serum (FBS;  
498 Corning or Atlanta), penicillin and streptomycin (pen/strep, UCSF media production). Cells  
499 were passaged by detaching with a disposable cell scraper. HEK293T cells (ATCC) were  
500 cultured in DMEM with 10% FBS and pen/strep. Platinum-E (Plat-E) retroviral packaging cells  
501 (CellBioLabs) were a gift from Jason Cyster (UCSF) and were maintained in DMEM  
502 supplemented with 10% FBS, pen/strep, glutamine, and 10mM HEPES (UCSF media  
503 production). Plat-E and HEK293T cells were passaged by detaching cells using 0.05%  
504 Trypsin-EDTA (UCSF media production). WT C57BL/6J (stock 000664), Rosa26-Cas9 (stock  
505 26179), *C3ar*<sup>-/-</sup> (stock 33904), *C3*<sup>-/-</sup> (stock 29661), and DBA2/J (stock 000671) mice were  
506 obtained from Jackson Laboratories and bred in the UCSF mouse barrier facility. Bone marrow  
507 from 6-to 8-week-old female mice was isolated from femurs and tibiae, and differentiated into  
508 bone marrow-derived macrophages (BMDMs) by culturing in BMM (bone marrow macrophage  
509 media) + 10mM HEPES as described previously(85). BMM contains 10% CMG-conditioned  
510 media and 20% FBS. Mammalian cells were frozen in complete media supplemented with 10%  
511 DMSO and 50% FBS, and stored in liquid nitrogen. *Histoplasma capsulatum* (*Hc*) strain  
512 G217B (ATCC 26032) and G217B *ura5* $\Delta$  were kind gifts from William Goldman (University of  
513 North Carolina, Chapel Hill). mCherry-expressing *Hc* was generated as described



514 previously(86). The *Hc cpb1* mutant strain, G217Bura5 $\Delta$ cbp1::T-DNA with a Ura5-containing  
515 episomal vector, was generated previously(7, 9). *Hc* cultures were grown on *Histoplasma*  
516 macrophage medium (HMM) agarose plates or in liquid HMM on an orbital shaker as  
517 previously described(87). Mammalian cells and *Hc* cultures were maintained in humidified  
518 tissue-culture incubators at 37°C with 5% CO<sub>2</sub>. *Hc* was grown on HMM-agar plates  
519 (supplemented with 0.175 mg/mL uracil to grow *Hc ura5* $\Delta$ ) for 1-2 weeks, and passaged in  
520 1:25 HMM liquid culture every-other day for five days to obtain logarithmic-phase *Hc* yeast-  
521 cultures (OD<sub>600</sub>=5-7). Yeast cells were collected, resuspended in Ca<sup>++</sup> and Mg<sup>++</sup>-free D-PBS  
522 (D-PBS), sonicated for 3 seconds on setting 2 using a Fisher Scientific Sonic Dismembrator  
523 Model 100, and counted using a hemocytometer. *Hc* yeast were adjusted to the appropriate  
524 concentration in D-PBS. For macrophage infections, *Hc* was added to the macrophage  
525 cultures, and allowed to settle onto the cells unless otherwise specified. *Candida albicans* (*Ca*)  
526 strain Sc5314 (ATCC MYA-2876) was a kind gift from Alexander Johnson (UCSF). *Ca* was  
527 grown on YEPD (2% peptone, 1% yeast extract, 2% glucose) agar or liquid media at 30°C.  
528 *Coccidioides posadasii* Silveira strain was a generous gift from Dr. Bridget Barker (Northern  
529 Arizona University). *Coccidioides* arthroconidia were obtained as previously described(88), by  
530 growing *Coccidioides* on 2xGYE (2% glucose 1% yeast extract) solid agar in flasks at 30°C for  
531 4-6 weeks. At the time of collection, arthroconidia were dislodged with a cell scraper in PBS,  
532 filtered through miracloth to remove hyphal fragments, resuspended in PBS and stored at 4C  
533 for up to 6 months. Arthroconidia concentration was measured by counting arthroconidia on  
534 hemocytometer.

535 **Generation of stable J774A.1 cell-lines for CRISPRKO and live-cell imaging experiments**

536 Gene-targeting sequences were cloned into the pMCB306 lentiguide-puro vector as  
537 previously described(89). Table S3 lists the targeting sequences used. The lentiviral Lifeact-  
538 monomeric eGFP-Blast vector was a kind gift from Diane Barber (UCSF). The Ef1a-Cas9-Blast  
539 lentiviral vector (pMCB393) was generated previously(48). To generate lentivirus particles,  
540 HEK293T cells were transfected using polyethylenimine (PEI) with second-generation (sgRNA,  
541 Lifeact) or third-generation (Ef1a-Cas9-Blast) packaging plasmids and the desired transfer  
542 plasmid. Lentivirus was 48-and 72-h later, and filtered through a 0.45  $\mu\text{m}$  polyvinylidene  
543 fluoride (PVDF) or polyethersulfone (PES) filter (Millipore). Viruses were concentrated using  
544 the Lenti-X concentrator (Takara) according to the manufacturer's instructions. Concentrated  
545 lentivirus (Cas9: 20X, lentiguide-puro: 1-2X, Lifeact: 5X) was added to J774A.1 cells for 12-24  
546 h (with 8  $\mu\text{g}/\text{mL}$  polybrene for Cas9), after which virus-containing media was removed and  
547 cells were grown in complete DMEM. Starting at 3 days post-transduction, cells were grown  
548 under selection with Blasticidin (2  $\mu\text{g}/\text{mL}$ ) or puromycin (2.5  $\mu\text{g}/\text{mL}$ ) for 3 days, and expanded  
549 without selection for at least 3 days or until the desired number of cells was obtained. To  
550 obtain clonal Cas9-expressing J774A.1 cells, live cells were harvested and single-cell sorted  
551 using a FACSAriaII cell-sorter into 96-well plates containing complete media supplemented  
552 with 50% sterile-filtered J774A.1 conditioned media, and expanded for 3 weeks. The Cas9  
553 activity of the J7-Cas9 clones was determined following transduction with the lentiguide-puro-  
554 eGFP vector containing a GFP-targeting sgRNA, and measuring eGFP silencing after  
555 puromycin selection by flow cytometry. The J7-Cas9 clone with the highest eGFP-silencing  
556 activity was used to generate the pooled CRISPR libraries and individual CRISPRKO cell-  
557 lines. The efficiency of Cas9-mediated gene-targeting was assessed by PCR-amplifying the

558 targeted locus in control and CRISPRKO cells, performing Sanger sequencing, and analyzing  
559 sequencing chromatograms using the TIDE webtool(90).

### 560 **Pooled CRISPR-Cas9 screens**

561 We used pooled mouse sgRNA sub-libraries that were generated previously(48), some  
562 of which are available on Addgene (#1000000121-1000000130). Each library covers 500-1500  
563 genes with 10 sgRNAs/gene and includes 750 negative control sgRNAs (375 non-targeting  
564 and 375 safe-targeting sgRNAs). We performed screens on all of the sub-libraries, except for  
565 the Mouse Unique sub-libraries, which contain mouse genes that do not have known  
566 orthologues in humans. Taken together, our screens covered 16,781 mouse genes. Lentivirus  
567 was generated by transfecting HEK293T cells seeded in 15 cm dishes with sgRNA plasmids  
568 and second-generation packaging plasmid as described previously(91). Lentivirus was  
569 harvested at 48-and 72-h post-transfection, filtered through 0.45 µm PES filters, pooled, then  
570 concentrated using the Lenti-X concentrator (Takara) according to the manufacturer's  
571 instructions. J774A.1 cells stably expressing LentiCas9-Blast (generation described above)  
572 were incubated with 2X concentrated lentivirus for 24h at 1000X coverage in T-225 or T175  
573 flasks for an MOI of 0.2-0.5 as determined by flow cytometry of mCherry expression at 3 days  
574 post-transduction. We then performed selection for transductants using puromycin (2.5 µg/mL)  
575 for 3 days until >90% of the cells were mCherry-positive by flow cytometry. Cells were allowed  
576 to recover from puromycin selection for three days before screening. Cells were split into two  
577 conditions, and screening was performed in duplicate. One condition was infected with *Hc*  
578 *ura5Δ* and subjected to 2-3 pulses of uracil to initiate fungal growth and macrophage lysis (see  
579 Table S2 for details specific to each sub-library). J774A.1 CRISPRKO libraries, seeded at

580 1000X library coverage in T-225 or T-150 flasks, were infected with *Hc ura5Δ* at a multiplicity  
581 of infection (MOI) of 5 yeast/macrophage. Yeast were allowed to settle onto the monolayer and  
582 incubated for 2 h. The cells were washed once with D-PBS to remove extracellular yeast, and  
583 incubated in the presence of 0.35 mg/mL uracil for 2 d until ~50% of the monolayer was  
584 cleared. Then, the monolayer was washed 3X with D-PBS to remove dead macrophages and  
585 extracellular yeast, and incubated for 2-5 days in complete media without uracil to allow the  
586 monolayer to recover. Then, uracil was re-introduced to the culture media for 1-2 d to re-initiate  
587 fungal growth and lysis. The addition and removal of uracil was performed 1-2 times  
588 depending on the speed at which the monolayer recovered. Uninfected cells were passaged in  
589 parallel every 2 d by detaching adherent cells with a cell-scraper, counting using a  
590 hemocytometer, and re-seeding into new flasks at 1000X coverage. Uninfected cells were  
591 pulsed with uracil during passaging to match the *Hc* infection. At the end of the screening  
592 period, cells were washed and harvested by detaching with a cell-scraper. Genomic DNA was  
593 extracted from the cells using the DNA blood midi or maxi kit according to the manufacturer's  
594 instructions, with the inclusion of a brief centrifugation step after cell lysis to remove un-lysed  
595 *Hc* yeast before addition of ethanol and application to the column. Guide frequencies were  
596 quantified by PCR amplification and deep sequencing using an illumina NextSeq 500 as  
597 previously described(89).

### 598 **Analysis of CRISPR-Cas9 Screens**

599 Sub-library screens were analyzed separately using castLE version 1.0 as previously  
600 described(50). Briefly, the distribution of guides was compared between the uninfected and  
601 *Hc*-infected samples, and guide enrichments were calculated as log ratios between the

602 infected and uninfected samples. A maximum likelihood estimator was used to estimate the  
603 effect size for each gene and the log-likelihood ratio (confidence score, or castLE score) by  
604 comparing the distribution of the 10 gene-targeting guides to the distribution of negative control  
605 guides. An effect size of 1 roughly corresponds to one log<sub>2</sub> fold change of the gene compared  
606 to the negative controls. P values were determined by permuting the gene-targeting guides in  
607 the screen and comparing to the distribution of negative controls using castLE, and false  
608 discovery rate (FDR) thresholds for defining hits were calculated using the Benjamini-  
609 Hochberg procedure. We used a threshold of 5% FDR to define hits. Results from the separate  
610 sub-library screens were concatenated and visualized together using JavaTreeview(92). GO-  
611 biological process analysis was performed using Gorilla(93) using an un-ranked list of genes  
612 that passed the 5% FDR cutoff as the target list and all of the genes detected in the screen as  
613 the background list.

#### 614 **Competitive fitness assays in J774A.1 cells**

615 J774A.1-Cas9 (WT) cells were mixed with CRISPRKO J774A.1-Cas9 cells harboring  
616 the lentiguide-puro vector, which drives expression of a gene-targeting sgRNA and an eGFP  
617 marker (75% WT cells, 25% CRISPRKO cells).  $3.5 \times 10^5$  cells/well were seeded in tissue  
618 culture (TC)-treated 6-well plates. 12-24 h later, the cells were infected with *Hc ura5Δ* at an  
619 MOI=5, which was incubated with the monolayer for 2 h followed by a D-PBS wash step. The  
620 cells were incubated in complete media containing 0.35 μg/mL uracil for 2 d, until lysis of >50%  
621 of the monolayer was observed. Then cells were recovered by washing 3X with D-PBS, and  
622 incubating in complete media in the absence of uracil for 2 d. Uninfected cells were detached  
623 by scraping and passaged to prevent overcrowding, and were subjected to the same washing

624 and media conditions as the *Hc*-infected cells. Following the recovery period, surviving cells  
625 were harvested and stained, and GFP-expression was analyzed by flow cytometry.

## 626 **Generation of CRISPR-knockout BMDMs**

627 The pSIN MuLV sgRNA retroviral transfer plasmid (U6 guide tracer EF1a Thy1.1 P2A  
628 Neo) was a kind gift from Jason Cyster (UCSF). The sgRNA cloning site, U6 promoter, and  
629 selection marker of pSIN was replaced to match that of pMCB306 using the Gibson Assembly  
630 Cloning Kit (NEB) to generate the transfer plasmid (BAS2186) used for these studies. Gene-  
631 targeting sgRNA sequences (Table S3) were cloned into the vector as previously described for  
632 pMCB306(89). To generate viral particles for expression of sgRNAs, Plat-E retroviral  
633 packaging cells were transfected with the transfer plasmid in antibiotic-free complete DMEM.  
634 Virus was harvested at 48 h and 72 h post-transfection and filtered through a 0.45µm PES  
635 filter. Bone marrow from female 6-8-week-old Rosa26-Cas9 mice was isolated and cultured for  
636 2 d in BMM as described above. Non-adherent bone marrow cells were harvested, and  $2 \times 10^6$   
637 cells per well were infected with 2 mL fresh MuLV supernatant by centrifugation (2400 RPM, 2  
638 h, RT) in 6-well non-TC-treated plates with 10 µg/mL polybrene. Viral supernatant was  
639 removed, and cells were incubated overnight in BMM. Both adherent and non-adherent bone  
640 marrow cells were infected with viral supernatant again as described above with the 72h viral  
641 harvest. 24h after the second viral spinfection, BMDMs were grown under puromycin selection  
642 (4 µg/mL) for 3 days, grown for an additional 3-5 days in BMM without puromycin, and  
643 harvested as previously described. Retroviral infection and selection were verified by Thy1.1  
644 staining and flow cytometry. The efficiency of Cas9-mediated gene-targeting was assessed by

645 PCR-amplifying the targeted locus in control and CRISPRKO cells, performing sanger  
646 sequencing, and analyzing sequencing chromatograms using the TIDE webtool(90).

#### 647 **Competitive *Hc* phagocytosis assays**

648 WT and CRISPRKO J774A.1 cells were mixed as described above (75% WT and 25%  
649 CRISPRKO), and seeded at  $3 \times 10^5$  cells/well in tissue-culture-treated 12-well plates and  
650 incubated for 12-24 h prior to infection. *Hc* yeast expressing mCherry were added to the  
651 monolayers at an MOI=2, and incubated for 1h at 37°C. Cells were then washed with ice-cold  
652 HBSS and harvested by pipetting the cells off of the well with HBSS. Similarly, Cas9-  
653 expressing BMDMs (WT) were mixed with Cas9-BMDMs transduced with a retroviral vector  
654 driving expression of a gene-targeting sgRNA (CRISPRKO) (75% WT and 25% CRISPRKO).  
655 BMDMs were added at  $5 \times 10^5$  cells/well to non-TC-treated 12-well plates in BMM for 12-24 h,  
656 then infected with mCherry-expressing *Hc* for 1 h in BMM. Phagocytosis and GFP or Thy1.1  
657 expression was measured using flow cytometry.

#### 658 **FITC labelling of Zymosan and *Coccidioides posadasii* arthroconidia**

659 FITC-labelling was performed as described previously for *Hc* yeast(16). Briefly,  
660 Zymosan A (Sigma) was sonicated for 3 seconds on setting 2 using a Fisher Scientific Sonic  
661 Dismembrator Model 100, washed with 0.05 M sodium carbonate-bicarbonate buffer, and  
662 adjusted to  $2 \times 10^8$  particles/mL. *C. posadasii* arthroconidia were adjusted to  $5 \times 10^8$  conidia/mL,  
663 and washed in a sodium carbonate-bicarbonate buffer. Fungi were incubated with in 0.05M  
664 sodium carbonate-bicarbonate buffer (pH 9.5) with 0.16mg/mL FITC (Fisher, dissolved in  
665 DMSO at 5mg/mL) for 15 min at room temperature, protected from light, then washed twice  
666 with HBSA (HBSS + 0.25% BSA). Labelled zymosan was resuspended in D-PBS, counted

667 using a hemocytometer, and frozen in single-use aliquots at -20°C. FITC-labelled arthroconidia  
668 were resuspended in PBS and counted on a hemocytometer. FITC-labelled arthroconidia were  
669 kept at 4°C and protected from light until used in phagocytosis experiments.

#### 670 **Mouse serum collection**

671 Mice were euthanized using CO<sub>2</sub>, and blood was collected by cardiac puncture. Blood  
672 was placed in a 1.5 mL Eppendorf tube and allowed to coagulate by incubation at room  
673 temperature for 1 h, and for an additional 30 min on ice. Coagulated blood was centrifuged,  
674 and the supernatant was harvested. Serum was used fresh or stored at -80°C in single-use  
675 aliquots.

#### 676 **BMDM phagocytosis assays**

677 BMDMs were thawed and seeded in BMM in 12-well non-TC-treated plates at 5X10<sup>5</sup>  
678 cells/well (flow cytometry) or onto ethanol-sterilized glass coverslips in TC-treated 24-well  
679 plates at 2X10<sup>5</sup> cells/well (microscopy), and allowed to adhere for 12-24 h. Prior to infection,  
680 the cells were washed with D-PBS and fresh media was added. For some experiments,  
681 BMDMs were pre-treated with the following inhibitors or vehicle controls: pertussis toxin  
682 (Sigma, 1 µg/mL 2 h), SB290157 (Sigma, 1 µM 5 min), anti-CD18 clone GAME-46 or isotype  
683 control (BD, 10 µg/mL 90 min). To ensure a consistent MOI across BMDM harvests, prior to  
684 infection a well of BMDMs was harvested using dissociation buffer, and counted using a  
685 hemocytometer. The count was used to calculate the number of BMDMs that had adhered to  
686 the dish to determine the number of fungal cells or particles to add to the well for the  
687 appropriate MOI. For *Hc* phagocytosis assays, mCherry-expressing *Hc* yeast was added to the  
688 macrophage monolayer. For Zymosan phagocytosis assays, FITC-labelled zymosan was



689 sonicated and added to the monolayer. Fluorescein-conjugated *E. coli* bioparticles (Invitrogen)  
690 were prepared according to the manufacturer's instructions and added to macrophage  
691 monolayers at an MOI=4. Carboxylate-modified microspheres (2.0  $\mu\text{m}$  and 0.5  $\mu\text{m}$ ) were  
692 sonicated and added to the macrophage monolayers at an MOI of 2. Phagocytosis of the  
693 above substrates was analyzed by flow cytometry. Logarithmic cultures of *Candida albicans*  
694 yeast grown in YEPD liquid media were harvested, washed 3X with D-PBS, counted, and  
695 added to macrophage monolayers on coverslips at an MOI of 3. Coverslips were washed 2X  
696 with DPBS and stained with 35  $\mu\text{g}/\text{mL}$  calcofluor white for 1 min. Then, the coverslips were  
697 washed, fixed with 4% PFA at 37°C for 20 min. PFA was quenched by washing 3X with 100  
698 mM glycine. Cells were permeabilized with 0.1% Triton-X-100 (5 min), and blocked with 1%  
699 BSA. Both intracellular and extracellular *C. albicans* yeast were detected by staining with a  
700 FITC-conjugated anti-*C. albicans* antibody (abcam, 1:1000) overnight 4°C. FITC-labelled *C.*  
701 *posadasii* arthroconidia were added to the coverslip an MOI of 1, then spun for 15 min at 550g  
702 to ensure contact between macrophages and arthroconidia. At the indicated times, the  
703 coverslips were washed and stained with 35  $\mu\text{g}/\text{mL}$  CFW (2 min), washed once, fixed with 4%  
704 PFA, then washed with PBS. For *C. albicans* and *C. posadasii* experiments, Coverslips were  
705 mounted and imaged at 40X magnification. 16 fields along a grid were automatically selected.  
706 To determine the phagocytosis rate, the cell-counter plugin in FIJI was used to manually count  
707 the total number of macrophages and the number of macrophages with at least one  
708 intracellular fungus, determined by exclusion of CFW staining. The phagocytosis rate was  
709 calculated as the number of macrophages with at least one intracellular fungal particle divided  
710 by the total number of macrophages.

711 **Serum opsonization and analysis of C3 deposition by immunofluorescence microscopy**

712 *Hc* or zymosan was incubated at  $1 \times 10^8$  particles/mL with 10% serum and the indicated  
713 chelators (10 mM EGTA or EDTA) in PBS for 30 min at 37°C. The yeast/particles were washed  
714 2X with PBS, and co-cultured with BMDMs, or stained with a FITC-conjugated anti-mouse C3  
715 antibody (MP Biomedicals, 1:200) for 1h at RT. Following staining, yeast/zymosan were  
716 washed 2X with PBS, and fixed with 4% PFA after spinning onto poly-L-Lysine-coated  
717 coverslips. Coverslips were washed 2X and imaged at 60X magnification to visualize mouse  
718 C3 deposition on the cell-wall.

719 **Analysis of C3aR localization by immunofluorescence microscopy**

720  $2 \times 10^5$  BMDMs were seeded onto ETOH-sterilized glass coverslips in 24-well plates.  
721 Phagocytosis was synchronized by pre-incubating macrophage monolayers on ice, and  
722 centrifuging mCherry *Hc* yeast or fluorescent latex beads (MOI=5) at 4°C onto the monolayers,  
723 followed by incubation at 37°C for up to 30 min. Coverslips were washed with D-PBS and fixed  
724 with 4% PFA for 20min at RT. Coverslips were blocked with PBS + 5% FBS for 1 h at RT, and  
725 stained with an anti-mouse C3aR antibody (Clone 14D4, Hycult, 1:1000) overnight at 4°C in  
726 5% FBS. Coverslips were washed with 5% FBS and stained with AlexaFluor-488-conjugated  
727 goat anti-rat IgG (Invitrogen, 1:500) for 1 h at RT. Coverslips were imaged at 60X  
728 magnification. Optical sectioning was performed to obtain Z-stacks (0.4  $\mu\text{m}$  step-size, 5  $\mu\text{m}$   
729 thickness), and 6 fields were imaged per coverslip. To quantify C3aR localization to the *Hc* or  
730 bead-containing phagosome, we used imageJ to define the phagosome perimeter using  
731 thresholding and binary operations on the *Hc* or the bead channels. Then, we use the 3D ROI  
732 manager(94) plugin on imageJ to quantify the mean intensity of the C3aR signal within the

733 phagosomal volume. We subtracted the background signal, measured on phagosomes in  
734 *C3ar*<sup>-/-</sup> BMDMs subjected to the same staining and analysis pipeline.

### 735 **Live cell-imaging and cell tracking**

736  $5 \times 10^3$  Lifeact-meGFP-expressing J774A.1 macrophages (generated as described in  
737 “generation of stable cell-lines”) were seeded into 96-well glass-bottom plates (Cellvis) and  
738 allowed to adhere for 12-24 h. Culture media was replaced with fresh phenol-red-free DMEM  
739 containing 10% FBS with either a vehicle control (DMSO) or 10  $\mu$ M C3aR antagonist  
740 (SB290157) and incubated for 5 min. mCherry-expressing were added to the cells at an MOI of  
741 5, and centrifuged briefly (15 sec) to facilitate contact with the macrophages. Cells were  
742 imaged every 90 sec for 45 min at 20X magnification. An Okolab stagetop incubator with  
743 temperature and humidity control was used to maintain optimal conditions (37°C and 5% CO<sub>2</sub>).  
744 Four fields were imaged per duplicate well. Actin-rich (eGFP+) membrane protrusions of  
745 macrophages that capture *Hc* yeast were tracked manually using the imageJ plugin  
746 MtrackJ(95). Tracking was started at the membrane point closest to the *Hc* yeast when the  
747 yeast first appeared close to the location at which it was eventually captured. The position of  
748 the yeast was used as a reference. The track was terminated when the *Hc* was successfully  
749 engulfed (as visualized by formation of an actin collar around the *Hc* yeast), or when the  
750 imaging period terminated. The phagocytosis rate is reported as the distance from the J774A.1  
751 cell-membrane to the *Hc* target at the start of tracking divided by the time elapsed until the  
752 yeast was successfully engulfed. The mean velocity (mean displacement/time across tracked  
753 points) and outreach ratio of the tracks (the max displacement/net displacement) were  
754 calculated as described(73).

755 **Confocal microscopy**

756 For fixed imaging, coverslips were mounted onto slides using vectashield antifade  
757 mounting media, with or without DAPI (Vector labs) and sealed using nail polish. Fluorescence  
758 confocal microscopy was performed using a using a Nikon Ti-Eclipse inverted microscope with  
759 a Yokogawa spinning disk CSU-X1 and an Andor Clara CCD camera. Image analysis was  
760 performed using FIJI (ImageJ).

761 **Flow cytometry**

762 BMDMs were washed and harvested using HBSS-based cell dissociation buffer  
763 (Thermo scientific) by incubating at 37°C for 10 min and pipetting with ice-cold HBSS. J774A.1  
764 cells were washed with ice-cold HBSS, and harvested by spraying cells off of the well with ice-  
765 cold HBSS using a P1000 pipette. Cells were kept on ice and protected from light for  
766 subsequent steps. Cells were stained with fixable viability dye efluor450 (ebioscience; 1:1000)  
767 for competitive fitness assays and CD11b/CD18 staining, or fixable viability dye efluor780  
768 (ebioscience; 1:500) for phagocytosis assays for 20 min. Cells were washed with FACS buffer  
769 (2% FBS and 5 mM EDTA in PBS) prior to staining with antibodies and/or Calcofluor White  
770 M2R (Sigma, 1 µg/mL) in FACS buffer for 15-20min. The following antibodies and dilutions  
771 were used: PerCP-conjugated anti-Thy1.1 (clone OX-7, biolegend, 1:100), PE, FITC, or  
772 AlexaFluor647-conjugated anti-CD11b antibody (clone M1/70, UCSF mAB core, 1:500 for  
773 BMDMs, 1:1000 for J774A.1), and AlexaFluor-647-conjuaged anti-CD18 antibody (M18/2,  
774 Biolegend, 1:100). Cells were washed with FACS buffer. For phagocytosis and competitive  
775 fitness assays, cells were washed with D-PBS, and fixed using BD stabilizing fixative for  
776 15min, washed with D-PBS, and kept on ice prior to data acquisition. For indirect flow

777 cytometry measurement of C3aR expression,  $5 \times 10^5$  BMDMs were fixed using BD stabilizing  
778 fixative (20min on ice). Cells were blocked for 20min with PBS5 (PBS+5% FBS) and stained  
779 with a C3aR antibody (Clone 14D4, Hycult, 1:500) in PBS5 for 20min on ice. Cells were  
780 washed with PBS5 and stained with APC-conjugated goat anti-rat IgG (Biolegend, 1:200) for  
781 20 min. Cells were washed with PBS5, and resuspended in PBS for flow cytometry analysis.  
782 Flow cytometry acquisition was performed using a BD LSRII analyzer in the UCSF Parnassus  
783 Flow Core (RRID:SCR\_018206). Analysis was performed using FlowJo v. 7 or 10. Where  
784 necessary compensation was performed with single-color controls using FlowJo.

### 785 **Trans-well migration assay**

786 Cells and *Hc* were resuspended in migration media (DMEM with 0.5% fatty acid-free  
787 BSA, pen/strep, and 10 mM HEPES) or complete DMEM with 10% FBS. Inhibitors were added  
788 to both the well and the insert when used. 6.5 mm transwell permeable supports with 5  $\mu$ m  
789 pore polycarbonate membranes (Costar) were used. Migration assays were performed in  
790 duplicate. 600  $\mu$ L *Hc* G217B yeast was added at the indicated concentration to the well of a  
791 24-well transwell plate.  $2 \times 10^5$  J774A.1 cells in 100  $\mu$ L media were seeded into the transwell  
792 insert, and plates were incubated at 37°C with 5% CO<sub>2</sub> for 3 h with minimal disturbance. Media  
793 was removed from the insert, which was dipped once in D-PBS, then placed in crystal violet  
794 stain (0.5% crystal violet, 20% methanol) for 10 min at RT. Supports were rinsed with dH<sub>2</sub>O,  
795 and a Q-tip was used to gently wipe cells off of the top of the membrane, and dried at RT.  
796 Membranes were mounted on slides, and 3 fields per membrane were imaged using a Leica  
797 DM 1000 microscope at 10X magnification. Cells in each microscopic field were counted  
798 manually using the cell counter plugin in FIJI.

799 **Cytotoxicity assays**

800 7.5X10<sup>4</sup> BMDMs were seeded per well of a 48-well plate and infected with *Hc* G217B at  
801 an MOI of 0.5 in the presence of pheno-red-free BMM. 1.875X10<sup>4</sup> J774A.1 cells were seeded  
802 per well of a 48-well plate and infected with *Hc* at an MOI of 5 in phenol-red-free complete  
803 DMEM. Where indicated, media was supplemented with 0.35mg/mL uracil. To recover  
804 J774A.1 cells from infection with *Hc ura5Δ*, cells were washed with D-PBS, and grown in  
805 complete media that did not contain uracil for 3 days. Recovered cells were re-seeded and  
806 incubated with complete media with or without uracil supplementation. At the indicated time  
807 points, the amount of lactate dehydrogenase (LDH) in the culture supernatant was measured  
808 as described previously(96). Macrophage lysis is calculated as the percentage of total LDH  
809 from uninfected macrophages lysed in 1% Triton-X at the time of infection. Due to continued  
810 replication of macrophages during the experiment, the total LDH at later time points is greater  
811 than the total LDH from the first time point, resulting in an apparent lysis that is greater than  
812 100%. To quantify cell depletion and recovery during infections of J774A.1 cells, we measured  
813 macrophage DNA remaining in the wells as previously described(10). Briefly, we washed the  
814 cells with D-PBS, added ddH<sub>2</sub>O to the well to lyse the macrophages, and measured the  
815 amount of macrophage DNA in the wells using the picoGreen DsDNA reagent (Invitrogen).  
816 Fluorescence intensities were measured using the quantitative plate read option on an  
817 Mx3000P QPCR machine (Agilent).

818 **Intracellular fungal growth assay**

819 7.5X10<sup>4</sup> BMDMs were seeded per well of a 48-well plate and infected in triplicate with  
820 *Hc* at an MOI of 0.5. At the indicated time points, culture supernatants were removed and 500

821  $\mu\text{L}$  ddH<sub>2</sub>O was added. Macrophages were osmotically and mechanically lysed, and plated on  
822 HMM agarose at the appropriate dilutions as described previously(7). After incubation at 37°C  
823 with 5% CO<sub>2</sub> for 12-14 days, colony forming units (CFUs) were enumerated. To prevent  
824 analysis of extracellular replication, CFUs were not monitored after the onset of macrophage  
825 lysis.

## 826 **CBA and ELISA assays**

827 BMDMs were seeded at  $3 \times 10^5$  cells/well in 48-well plates (TC-treated), and infected  
828 with *Hc* in triplicate (MOI=10 for CBA and MOI=2 for C3 ELISA). Supernatants were collected  
829 at the indicated times and either used fresh for assays or snap-frozen in LN<sub>2</sub> and stored at -  
830 80°C. Supernatants were filtered using Spin-X cellulose acetate spin filters (Costar) by  
831 centrifugation. TNF- $\alpha$  was measured using the mouse TNF CBA flex set (BD) according to the  
832 manufacturer's instructions. Data were acquired using a BD LSRII flow cytometer and  
833 analyzed using FCAP array software (BD). The colorimetric Mouse Complement C3 ELISA kit  
834 (Abcam) was used according to the manufacturer's instructions to quantify C3 levels in  
835 macrophage culture supernatant. Mouse serum was incubated with *Hc* and zymosan at  
836  $10 \times 10^8$  particles/mL for 30 min at 37°C. The reaction was stopped by addition of 10 mM EDTA  
837 and incubation on ice. *Hc* and zymosan were pelleted by centrifugation, and the supernatant  
838 was filtered using Spin-X cellulose acetate filters. Supernatants were diluted 1:200. A mouse  
839 C3a ELISA pair (BD) was used as previously described(97) according to manufacturer's  
840 instructions to measure C3a levels in the supernatants. Corning High-Bind plates were coated  
841 with 4  $\mu\text{g/mL}$  capture antibody in pH 6.5 binding buffer. PBS+10% FBS was used for blocking,  
842 and PBS+ $\Delta$ 10% FBS +0.05% Tween-20 was used to dilute samples, standards, and detection

843 antibody solutions. Biotinylated C3a detection antibody was used at 6.25 ng/mL, and avidin-  
844 HRP was used at a 1:5000 dilution.

845 **Ethics statement**

846 All mouse experiments were performed in compliance with the *National Institutes of*  
847 *Health Guide for the Care and Use of Laboratory Animals* and were approved by the  
848 Institutional Animal Care and Use Committee at the University of California San Francisco  
849 (protocol AN18753-03A). Mice were euthanized by CO<sub>2</sub> narcosis and cervical dislocation  
850 consistent with American Veterinary Medical Association guidelines.


851



852 **Figures and Legends**

853 **Figure 1: A pooled CRISPR screen identifies genes required for macrophage susceptibility to**


854 **infection with *Hc***



855

856 **A.** Diagram of screen approach. Cas9-expressing J774A.1 macrophage-like cells were  
857 transduced with a library of sgRNAs, challenged with Ura5-deficient *Hc* yeast, and subjected to  
858 2-3 pulses of uracil treatment followed by recovery. sgRNAs amplified from *Hc*-infected and  
859 uninfected cells were deep-sequenced, and sequences were analyzed to identify guides that  
860 became enriched or depleted in the *Hc*-infected pool relative to the uninfected pool. **B.** Volcano  
861 plot showing the confidence score (casTLE score) versus the effect size (casTLE effect) for all  
862 genes. Genes that pass the 5% FDR cutoff are colored red, and genes individually validated in  
863 J774A.1 cells are labelled and colored in blue. **C.** Adjusted P-values for selected GO biological  
864 process annotations enriched in the screen hits. **D.** The 150 highest-scoring genes identified in  
865 the screen grouped based on their annotated function and localization in a cell, functional  
866 categories or complexes of genes are noted. Genes are colored according to their gene effect  
867 estimate, where yellow indicates enrichment in the *Hc* infected pool and blue indicates  
868 depletion.  
869

870 **Figure 2:** Identification of genes required for phagocytosis of yeast in J774A.1 cells and  
 871 primary macrophages




872

873 **A.** Diagram of approach used to individually validate the role of a gene in macrophage  
 874 susceptibility to *Hc* infection. A mixture of WT (GFP-) and CRISPRKO (GFP+) J774A.1 cells  
 875 with or were challenged with *Hc* yeast in the presence of uracil, and allowed to recover.  
 876 Uninfected cells from the same mixture were passaged in parallel, and the percentage of  
 877 mutant cells in the *Hc* infected pools was compared to that of the uninfected pools via flow

878 cytometry (n=3 biological replicates). **B.** Enrichment of gene-targeting guides in the *Hc* infected  
879 pool relative to the control pool, compared to that of non-targeting guides. **C.** Diagram of  
880 approach for determining the role of a gene in phagocytosis of *Hc*. A mixture WT (GFP-) and  
881 CRISPRKO (GFP+) J774A.1 cells were infected with mCherry-expressing *Hc* yeast. Non-  
882 internalized yeasts were excluded using calcofluor white staining. Flow cytometry was used to  
883 determine the representation of mutant cells in the phagocytic compared to the non-phagocytic  
884 populations (n=3). **D.** Identification of genes required for phagocytosis of yeast in J774A.1 cells  
885 using GFP expression to measure enrichment of sgRNA-expressing cells. **E.** Validation of  
886 gene involvement in BMDM phagocytosis of yeast using CRISPRKO BMDMs (Thy1.1+). A  
887 mixture of transduced (Thy1.1+) and untransduced (Thy1.1-) BMDMs were similarly infected  
888 with yeast and stained with calcofluor white and a Thy1.1 antibody to determine the  
889 representation of mutants in the phagocytic and non-phagocytic populations (n=3 biological  
890 replicates).

891 **Figure 3: C3aR signaling plays a role in macrophage phagocytosis of fungi**




892

893 **A.** WT and *C3ar*<sup>-/-</sup> BMDMs were infected with live and PFA-killed mCherry-expressing *Hc*  
 894 yeast, and the phagocytosis rate was monitored over-time using flow-cytometry (n=3 biological  
 895 replicates). **B.** WT and *C3ar*<sup>-/-</sup> BMDMs were infected with FITC-labelled zymosan or mCherry-  
 896 expressing *Hc* and the phagocytosis rate infected cells was monitored using flow cytometry  
 897 (n=3 biological replicates). **C.** BMDMs were infected with *Candida albicans* (*Ca*). Cells were  
 898 imaged using confocal microscopy to quantify phagocytosis (n=2 biological replicates, >350  
 899 cells/replicate). CFW staining was used to exclude extracellular *Ca*. **D.** BMDMs were infected  
 900 with FITC-labelled *Coccidioides posadasii* (*Cp*) arthroconidia, and extracellular conidia were  
 901 labelled with calcofluor white. BMDM infection rates were determined using confocal  
 902 microscopy (n=3 biological replicates, 200-400 cells/rep). **E.** BMDMs were infected with FITC-  
 903 labelled *E. coli* bioparticles and the *E. coli*-association with BMDMs was monitored via flow

904 cytometry (n=2 biological replicates). **F.** BMDMs were infected with 2  $\mu$ m or 0.5  $\mu$ m red  
905 fluorescent latex beads, and the rate of BMDM association with the beads was measured  
906 using flow cytometry (n=3 biological replicates). **G.** BMDMs were treated with a C3aR  
907 antagonist (1  $\mu$ M SB290157) and infected with *Hc* yeast. Phagocytosis was measured using  
908 flow cytometry (n=3 biological replicates). **H.** BMDMs were pre-treated for 2 h with 1  $\mu$ g/mL  
909 pertussis toxin (Ptx), which inhibits Gai, and infected with *Hc* (n=3 biological replicates). **I.**  
910 BMDMs were pre-treated for 90 min with 10  $\mu$ g/mL CD18 blocking antibody (GAME-46) and  
911 infected with *Hc* yeast (n=3 biological replicates) Phagocytosis was measured using flow  
912 cytometry. *Emc1* is required for C3aR expression in BMDMs (**J-L**). **J.** *Emc1* CRISPRKO  
913 BMDMs and control sgRNA transduced BMDMs were stained with an anti-C3aR antibody, and  
914 C3aR levels were measured via flow cytometry (n=2 biological replicates). **K.** Histogram of  
915 C3aR levels in control and *Emc1* CRISPRKO BMDMs. **L.** Frequency of C3aR+ cells in the  
916 indicated BMDMs. **M.** The mean fluorescence intensity (MFI) of the C3aR signal in the  
917 indicated BMDMs.  
918

919 **Figure 4: Serum C3 promotes complement opsonization and macrophage phagocytosis of *Hc***  
 920 yeast




921



922 **A.** FBS stimulates macrophage phagocytosis of fungi in a C3aR-dependent manner. BMDMs  
923 were infected with mCherry-expressing *Hc* or FITC-labelled zymosan in the presence or  
924 absence of 20% heat-treated FBS (FBS). Phagocytosis was assessed via flow cytometry (n=3  
925 biological replicates). **B.** FBS does not promote macrophage phagocytosis of *Hc* via  
926 opsonization. *Hc* and zymosan particles were pre-incubated with 10% heat-treated FBS for 30  
927 min at 37°C, washed, and used to infect BMDMs. Phagocytosis was measured using flow  
928 cytometry (n=2 biological replicates). **C.** Normal mouse serum (NMS) stimulates BMDM  
929 phagocytosis of fungi in a C3-dependenent manner. BMDMs were infected with *Hc* yeast in  
930 serum-free media or media supplemented with 5% FBS, 5% NMS from WT mice, 5% NMS  
931 from C3-/- mice, or 5% heat-inactivated NMS (hiNMS) from WT mice. BMDMs in serum-free  
932 media were also infected with *Hc* opsonized with 10% WT or C3-/- NMS. Phagocytosis was  
933 measured as described above (n=3 biological replicates). **D.** C5-deficient serum promotes  
934 macrophage phagocytosis of *Hc* in a C3aR-dependant manner. BMDMs were infected with *Hc*  
935 yeast in media supplemented with 5% NMS from C57BL/6 mice or DBA2 (C5-deficient) mice.  
936 Phagocytosis was measured as described above (n=2 biological replicates). **E-F.** Mouse  
937 serum promotes complement opsonization of yeast via multiple pathways. *Hc* (**E**) or Zymosan  
938 (**F**) were incubated in PBS with 10% sera from WT or C3-/- mice. 10 mM EGTA or EDTA were  
939 added to the reactions to chelate Ca<sup>2+</sup> or Mg<sup>2+</sup>, respectively. Yeast were stained with FITC  
940 conjugated anti-mouse C3, and imaged using confocal microscopy (representative slices are  
941 shown from 2 biological replicates). **G.** Incubation of *Hc* with mouse serum leads to C3a  
942 release. Supernatants were harvested following incubation of mouse serum with *Hc* or  
943 zymosan, and mouse C3a levels were measured by ELISA.




944 **Figure 5: C3aR localizes to the early *Hc*-containing phagosome**



945

946 C3aR localizes to *Hc*-containing phagosomes (**A**) to a greater extent than latex bead-  
947 containing phagosomes (**B**). BMDMs were infected with the indicated particles (MOI=5, n=2  
948 biological replicates per time point). Cells were then stained with a C3aR-specific antibody and  
949 imaged using optical sectioning with a confocal microscope. Representative images from a  
950 single slice are shown. **C**. The mean fluorescence intensity of C3aR in the particle-containing  
951 phagosomes was quantified using ImageJ (N>91 phagosomes).

952 **Figure 6:** C3aR promotes the formation of actin-rich protrusions that facilitate capture of *Hc*  
953 yeast




954

955 J774A.1 cells were engineered to express Lifect-mEGFP to label F-actin, co-cultured with  
956 mCherry-expressing *Hc* yeast, and subjected to live-cell confocal microscopy in a temperature-  
957 and-CO<sub>2</sub> controlled chamber in media supplemented with 10% FBS. Cells were treated with a  
958 C3aR antagonist (10 µM SB290157) or a vehicle control. **A.** Representative images from a  
959 confocal time series showing a macrophage extending an F-actin-rich protrusion towards an  
960 mCherry expressing *Hc* yeast, followed by phagocytosis and formation of an actin-rich  
961 phagosome. The corresponding DIC images are shown below. **B.** A similar time series of

962 macrophages treated with SB290157 showing a failure to initiate formation of a membrane  
963 protrusion and much slower capture of *Hc* yeast. The movement of membrane structures that  
964 successfully captured yeast were analyzed using MtrackJ to quantify the behaviors of these  
965 structures (**C-E**), including the phagocytosis rate, quantified as the time required for the  
966 macrophage to successfully engulf the yeast divided by the distance of the yeast to the  
967 macrophage at the start of the series (**C**), the mean velocity of the membrane structure closest  
968 to the yeast (**D**), and the outreach ratio quantified as the max displacement of the track divided  
969 by the length of the track (**E**). These metrics demonstrate that macrophages treated with the  
970 C3aR antagonist are defective at the extension of membrane protrusions in the direction of *Hc*  
971 yeast that facilitate phagocytosis.

972

973 **Figure 7:** Model for the role of complement and C3aR in macrophage recognition of *Hc* yeast



974

975 We propose the following model for the role of complement and C3aR in macrophage  
976 recognition of *Hc*: C3, derived from serum, reacts with the *Hc* cell-wall, leading to C3b/iC3b  
977 deposition on the cell-wall, and release of C3a, which diffuses away from the yeast surface  
978 leading to a concentration gradient emanating from the yeast cell-wall. C3a activates C3aR,  
979 which signals through Gai and Gβ2 to promote the formation and directional movement of  
980 actin-rich membrane protrusions, and possibly to promote activation or increased motility of the  
981 integrin receptor CR3. Active CR3 can then recognize C3b/iC3b or other features of the *Hc*  
982 cell-wall. C3aR and/or CR3 activation then coordinates actin polymerization and phagocytic


983 cup formation by regulating the activity of actin polymerization regulators Arp2/3 and

984 SCAR/WAVE.

985

986

987 **Figure S1:** Development and validation of Cas9-expressing J7 cell-lines, and validation of  
 988 screening approach.




989  
 990 **A.** Characterization of *Hc*-mediated lysis in J774A.1 macrophage-like cells. J774A.1 cells were  
 991 infected with WT *Hc*, or *Hc* with a disruption in a gene, *CBP1*, that is required for *Hc* to lyse  
 992 macrophages. Lysis over time was measured using the LDH release assay. **B.** Validation and  
 993 clonal expansion of Cas9-expressing J774A.1 cells. Cells were transduced with an Ef1a-Cas9-  
 994 Blast expression vector and grown under blasticidin selection to generate a population of  
 995 Cas9-expressing cells. These were subjected to single-cell sorting and clonal expansion to  
 996 generate Cas9-expressing J774A.1 clones with high Cas9 activity. Cas9 activity was  
 997 measured by transducing J774A.1 cells with a guide RNA vector that co-expressed EGFP with

998 a sgRNA targeting EGFP. Cas9 activity leads to silencing of the GFP following puromycin  
999 selection. Cas9 clone 9 was chosen for the large-scale CRISPR screens due to its high-  
1000 efficiency GFP silencing. **C-D.** Characterizing lysis and recovery from infection with uracil  
1001 pulses during infection with a Ura5-deficient *Hc. J774A.1* macrophages were infected with *ura5*  
1002 mutant *Hc* in the presence or absence of exogenous uracil (0.4ug/mL). Uracil-containing cells  
1003 were washed and media was replaced with uracil-poor media after 2d of lysis, which allowed  
1004 the macrophages to recover. Recovery was assessed using LDH release quantification to  
1005 assess lysis, and the confluency of viable cells in the wells was estimated using the pico-green  
1006 dsDNA assay kit following lysis of macrophages with water. **E.** macrophages that had been  
1007 recovered from lysis by removal of uracil from culture media were passaged for several days,  
1008 and uracil was added to selected wells. Macrophage lysis over time was monitored by  
1009 assessing LDH release over time to determine whether dormant yeast would be able to re-  
1010 activate upon introduction of uracil. **F.** Reproducibility of the castLE score across two  
1011 replicates of the screens. **G.** Histograms comparing the distribution of negative control sgRNAs  
1012 and sgRNAs targeting *Gnb2* or *C3ar* in the *H. capsulatum* infected pool compared to the  
1013 uninfected pool. **H.** Analysis of essential gene behavior during J7 library growth. Scatter plot  
1014 showing the gene effect resulting from passaging of J7s, either going from the plasmid pool to  
1015 the T0 pool, or the T0 pool to the uninfected pool. Genes annotated as “essential” or “non-  
1016 essential” were plotted to determine whether essential genes appeared more likely to drop out  
1017 of the uninfected pools.

1018

1019

1020 **Figure S2: Emc1 and C3aR are not required for surface expression of CD18 or CD11b**



1021

1022 BMDMs from *C3ar*<sup>-/-</sup> and WT mice, in addition to BMDMs expressing Cas9 and control or

1023 *Emc1*-targeting sgRNAs, were stained with anti-CD18 and anti-CD11b antibodies and

1024 analyzed by flow cytometry (n=2 biological replicates). **A.** Representative histograms showing

1025 CD11b and CD18 levels in control, *C3ar*<sup>-/-</sup>, and *Emc1* CRISPRKO BMDMs. The percentage of

1026 CD11b (**B**) and CD18 (**D**) positive macrophages was analyzed. The mean fluorescence


1027 intensity of CD11b (**C**) and CD18 (**E**) were also measured.

1028

1029



1030 **Figure. S3:** *C3ar*<sup>-/-</sup> BMDMs are partially resistant to *Hc*-induced lysis




1031

1032 BMDMs were infected with *Hc* (MOI=0.5), and macrophage lysis was quantified by measuring  
1033 the release of lactate dehydrogenase into the culture supernatants over-time (n=3 biological  
1034 replicates, 3 technical replicates/biorep) (A). At the indicated time points, macrophages were  
1035 lysed using water, and lysates were spread on agar plates. Colony forming units (CFUs) were  
1036 enumerated (n=3 biological replicates, 2 technical reps/biorep) (B).

1037


1038 **Figure. S4:** C3aR does not affect *Hc*-induced cytokine secretion by BMDMs.



1039

1040 WT and *C3ar*<sup>-/-</sup> BMDMs were infected with *Hc* (MOI=5 for 6 h), and TNF $\alpha$  levels in  
1041 macrophage supernatants were measured using the BD Cytometric Bead Array kit (n=3  
1042 biological replicates).

1043 **Figure S5:** Different lots of FBS stimulate BMDM phagocytosis of *Hc* in a C3aR-dependent  
1044 manner




1045

1046 **(A-C)** BMDMs from WT and *C3ar*<sup>-/-</sup> mice were infected with *Hc* in the presence of 20% FBS  
1047 from three different lots from 2 separate suppliers. In addition, WT BMDMs differentiated in  
1048 different lots of serum were treated with 10  $\mu$ M of the C3aR antagonist and infected with *Hc*  
1049 **(B)**. Phagocytosis of *Hc* was measured by flow cytometry as described previously (n=2  
1050 biological replicates).

1051

1052

1053 **Figure S6:** Macrophage conditioned media containing FBS does not promote opsonization  
1054 that facilitates macrophage phagocytosis of *Hc* yeast in the absence of serum




1055

1056 BMDMs were cultured in media containing 10% FBS, and the BMDM conditioned media was  
1057 harvested. *Hc* was incubated with macrophage conditioned media (BMDM CM), 10% FBS, or  
1058 10% normal mouse serum (NMS) with 10 mM EGTA or EDTA as indicated for 30 min 37°C. **A.**  
1059 Incubation with conditioned media or FBS does not lead to C3 deposition on the *Hc* surface.  
1060 C3 deposition on *Hc* yeast was analyzed by immunofluorescence microscopy using an anti-C3

1061 antibody. **B.** Pre-incubation of yeast with conditioned media does not improve macrophage  
1062 phagocytosis of *Hc*. Yeast were washed 2X and used to infect BMDMs at an MOI of 3 for 30  
1063 min in serum-free media. Phagocytosis was assessed using flow cytometry as previously  
1064 described (n=3 biological replicates).  
1065

1066 **Figure S7:** BMDM-derived C3 is not required for phagocytosis of *H. capsulatum* yeast or  
1067 zymosan particles




1068

1069 **A.** BMDMs secrete C3 following infection with *Hc*. BMDMs were infected with *Hc* at an MOI2  
1070 for 24h, supernatants were harvested and C3 levels were quantified using a BD mouse C3  
1071 ELISA kit. **B.** *C3-/-* BMDMs are not defective in phagocytosis of *Hc* yeast or zymosan. WT and  
1072 *C3-/-* BMDMs were infected with mCherry-expressing *H. capsulatum* or FITC-labelled  
1073 zymosan, and uptake over time was measured using flow-cytometry. Extracellular yeasts were  
1074 excluded with calcofluor white staining.

1075

1076 **Figure S8:** C3aR is localized to the plasma membrane in uninfected cells.



1077


1078 Uninfected WT and *C3ar-/-* BMDMs were stained with a C3aR-specific antibody and imaged  
1079 using confocal microscopy and optical sectioning. Representative slices of 2 biological

1080 replicates are shown. The antibody specifically detects C3aR, as staining was not observed in  
1081 *C3ar*<sup>-/-</sup> BMDMs. C3aR exhibits punctate localization near the plasma membrane in WT  
1082 BMDMs.

1083

1084

1085 **Figure S9:** Macrophage-like cells undergo chemotaxis towards *H. capsulatum* yeast in a  
1086 serum-independent manner, which is dependent on Gai, and partially dependent on C3aR




1087

1088 **A.** *Hc* stimulates chemotaxis of J774A.1 macrophage-like cells. *H. capsulatum* yeast were  
1089 seeded into multiple-well plates at varying concentrations, and WT J774A.1 cells were seeded  
1090 onto transwell permeable supports with 5 μm pores. Serum-free media supplemented with  
1091 0.25% BSA was used as the diluent in both the chamber and well unless otherwise indicated.  
1092 After 3 h of migration, transwells were stained with crystal violet, and non-migratory cells were  
1093 wiped off of the upper side of the transwell using a Q-tip. The number of migratory cells in each  
1094 condition was quantified by microscopy (n=2 biological replicates, 3 fields/biological replicate). **B.**

1095 Migration towards *Hc* is Gai-dependent. J774A.1 cells with or without pre-treatment with 1  
1096  $\mu\text{g}/\text{mL}$  pertussis toxin (PTX) for 2 h were seeded into transwell permeable supports and  
1097 migration towards  $1 \times 10^5$  *Hc*/uL was quantified as described above. The number of migrating  
1098 cells was quantified as described. **C.** The C3aR antagonist does not inhibit macrophage  
1099 migration towards *Hc*. J774A.1 macrophages were treated with  $1 \mu\text{M}$  SB290157, a C3aR  
1100 antagonist, and migration towards *H. capsulatum* was assessed as described. **D.** C3aR-  
1101 deficiency moderately impacts migration of J774A.1 cells towards *Hc*. Cas9-expressing  
1102 J774A.1 macrophages transduced with non-targeting or C3aR-targeting sgRNAs were  
1103 assessed for their ability to migrate towards *Hc* as described previously. **E.** *Hc*-dependent  
1104 migration is abolished in the presence of FBS. The transwell migration assay was performed  
1105 with media supplemented with BSA or 10% FBS to determine whether FBS affected the  
1106 migration of macrophage-like cells towards *Hc* yeast.

1107 **Figure S10:** pre-incubation on ice or spinfection do not rescue phagocytosis of fungi in C3aR-  
1108 *-* BMDMs




1109 **A.** BMDMs were infected with *Hc* or zymosan at an MOI=5 for 30 min. For the control  
1110 condition, particles were added to the wells and allowed to settle onto the monolayer without  
1111 intervention. For the 5 min spinfection, particles were added to the cells, and the plate was  
1112 spun for 5 min at 550XG at RT before transferring to a 37°C, 5% CO<sub>2</sub> incubator. For the ice  
1113 preincubation condition, BMDMs were pre-chilled for 20 min on ice, and particles were allowed  
1114

1115 to settle onto the monolayer for 1 h on ice, then were transferred to a tissue culture incubator.

1116 Phagocytosis was measured as described previously (n=3 biological replicates).

1117

1118 **Figure S11:** Addition of recombinant C3a is not sufficient to rescue phagocytosis of fungi in the  
1119 absence of serum.



1120

1121 BMDMs were pre-incubated in serum-free media with varying concentrations of recombinant

1122 mouse C3a (R&D systems) or with 20% FBS for 1 h, then infected with **A.** *Hc* or **B.** Zymosan

1123 at an MOI of 5 for 30 min. Phagocytosis was assessed by flow cytometry (n=2 biological

1124 replicates).

1125



1126 **Table S1:** results from CRISPR screens

1127 Upload data (CSVs with results from castLE analysis, either separated or concatenated)

1128 **Table S2:** Screen statistics summary by sub-library

Sub-library	Rounds of <i>Hc</i> -mediated lysis	Duration (days)	$\Delta$ divisions (uninf- <i>Hc</i> inf)	Correlation coefficient ( $R^2$ casTLE score)	#genes	# desensitizing hits ( <i>Hc/un</i> >0)	# sensitizing hits ( <i>Hc/un</i> <0)	Total hits
ACOCA	2	16	10.17	0.74	1568	31	1	32
ACOCB	3	10	7.93	0.57	1546	59	1	60
TMMA	2	9	9.9	0.69	972	43	4	47
TMMB	3	7	6.73	0.49	951	37	1	38
DTKPA	2	7	5.53	0.24	1008	20	1	21
DTKPB	2	8	4.9	0.48	1003	15	0	15
SPA	2	9	8.5	0.49	1333	31	9	40
SPB	2	9	8.45	0.68	1478	21	2	23
MPAB	3	10	6.2	0.73	953	14	4	18
GEA	2	8	5.6	0.54	954	9	6	15
GEB	2	9	6.2	0.46	962	14	4	18
U1A	2	8	5.2	0.19	1019	8	1	9
U1B	2	8	5.3	0.53	932	19	2	21
U2AB	2	8	6.3	0.0028	2103	1	3	4

1129

1130

1131 **Table S3:** sgRNAs used in this study

1132 Upload CSV

1133 **Table S4:** Oligonucleotides used in this study

1134 Upload CSV

1135 **References**

- 1136 1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Critical reviews in  
1137 microbiology. 2010;36(1):1-53.
- 1138 2. Deepe GS, Jr., Gibbons RS, Smulian AG. Histoplasma capsulatum manifests preferential invasion  
1139 of phagocytic subpopulations in murine lungs. J Leukoc Biol. 2008;84(3):669-78.
- 1140 3. Jones GS, Sepúlveda VE, Goldman WE. Biodiverse Histoplasma Species Elicit Distinct Patterns of  
1141 Pulmonary Inflammation following Sublethal Infection. mSphere. 2020;5(4).
- 1142 4. Horwath MC, Fecher RA, Deepe GS, Jr. Histoplasma capsulatum, lung infection and immunity.  
1143 Future microbiology. 2015;10(6):967-75.
- 1144 5. Garfoot AL, Rappleye CA. Histoplasma capsulatum surmounts obstacles to intracellular  
1145 pathogenesis. The FEBS journal. 2016;283(4):619-33.
- 1146 6. Ray SC, Rappleye CA. Flying under the radar: Histoplasma capsulatum avoidance of innate  
1147 immune recognition. Semin Cell Dev Biol. 2019;89:91-8.
- 1148 7. English BC, Van Prooyen N, Ord T, Ord T, Sil A. The transcription factor CHOP, an effector of the  
1149 integrated stress response, is required for host sensitivity to the fungal intracellular pathogen  
1150 Histoplasma capsulatum. PLoS pathogens. 2017;13(9):e1006589.
- 1151 8. Woods JP. Revisiting old friends: Developments in understanding Histoplasma capsulatum  
1152 pathogenesis. Journal of Microbiology. 2016;54(3):265-76.
- 1153 9. Isaac DT, Berkes CA, English BC, Hocking Murray D, Lee YN, Coady A, et al. Macrophage cell  
1154 death and transcriptional response are actively triggered by the fungal virulence factor Cbp1 during H.  
1155 capsulatum infection. Mol Microbiol. 2015;98(5):910-29.
- 1156 10. Sebghati TS, Engle JT, Goldman WE. Intracellular parasitism by Histoplasma capsulatum: fungal  
1157 virulence and calcium dependence. Science (New York, NY). 2000;290(5495):1368-72.
- 1158 11. Erwig LP, Gow NA. Interactions of fungal pathogens with phagocytes. Nature reviews  
1159 Microbiology. 2016;14(3):163-76.
- 1160 12. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, et al. Dectin-1 is  
1161 a major beta-glucan receptor on macrophages. The Journal of experimental medicine.  
1162 2002;196(3):407-12.
- 1163 13. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation of the innate  
1164 immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature. 2011;472(7344):471-5.
- 1165 14. Flannagan RS, Jaumouillé V, Grinstein S. The cell biology of phagocytosis. Annu Rev Pathol.  
1166 2012;7:61-98.
- 1167 15. Freeman SA, Grinstein S. Phagocytosis: receptors, signal integration, and the cytoskeleton.  
1168 Immunological reviews. 2014;262(1):193-215.

- 1169 16. Lin JS, Huang JH, Hung LY, Wu SY, Wu-Hsieh BA. Distinct roles of complement receptor 3,  
1170 Dectin-1, and sialic acids in murine macrophage interaction with *Histoplasma* yeast. *J Leukoc Biol.*  
1171 2010;88(1):95-106.
- 1172 17. Rappleye CA, Eisenberg LG, Goldman WE. *Histoplasma capsulatum* alpha-(1,3)-glucan blocks  
1173 innate immune recognition by the beta-glucan receptor. *Proceedings of the National Academy of*  
1174 *Sciences of the United States of America.* 2007;104(4):1366-70.
- 1175 18. Garfoot AL, Shen Q, Wuthrich M, Klein BS, Rappleye CA. The Eng1 beta-Glucanase Enhances  
1176 *Histoplasma* Virulence by Reducing beta-Glucan Exposure. *mBio.* 2016;7(2).
- 1177 19. Bullock WE, Wright SD. ROLE OF THE ADHERENCE-PROMOTING RECEPTORS, CR3, LFA-1, AND  
1178 P150,95, IN BINDING OF HISTOPLASMA-CAPSULATUM BY HUMAN MACROPHAGES. *Journal of*  
1179 *Experimental Medicine.* 1987;165(1):195-210.
- 1180 20. Tan SM. The leucocyte  $\beta 2$  (CD18) integrins: the structure, functional regulation and signalling  
1181 properties. *Biosci Rep.* 2012;32(3):241-69.
- 1182 21. Noris M, Remuzzi G. Overview of complement activation and regulation. *Semin Nephrol.*  
1183 2013;33(6):479-92.
- 1184 22. Wong SSW, Daniel I, Gangneux JP, Jayapal JM, Guegan H, Dellière S, et al. Differential  
1185 Interactions of Serum and Bronchoalveolar Lavage Fluid Complement Proteins with *Conidia* of Airborne  
1186 Fungal Pathogen *Aspergillus fumigatus*. *Infect Immun.* 2020;88(9).
- 1187 23. Bolger MS, Ross DS, Jiang H, Frank MM, Ghio AJ, Schwartz DA, et al. Complement levels and  
1188 activity in the normal and LPS-injured lung. *Am J Physiol Lung Cell Mol Physiol.* 2007;292(3):L748-59.
- 1189 24. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. *Nature*  
1190 *reviews Microbiology.* 2008;6(2):132-42.
- 1191 25. Torres-Gomez A, Cabañas C, Lafuente EM. Phagocytic Integrins: Activation and Signaling. *Front*  
1192 *Immunol.* 2020;11:738.
- 1193 26. Quell KM, Karsten CM, Kordowski A, Almeida LN, Briukhovetska D, Wiese AV, et al. Monitoring  
1194 C3aR Expression Using a Floxed tdTomato-C3aR Reporter Knock-in Mouse. *Journal of immunology*  
1195 (Baltimore, Md : 1950). 2017;199(2):688-706.
- 1196 27. Zwirner J, Werfel T, Wilken HC, Theile E, Gotze O. Anaphylatoxin C3a but not C3a(desArg) is a  
1197 chemotaxin for the mouse macrophage cell line J774. *European journal of immunology.*  
1198 1998;28(5):1570-7.
- 1199 28. Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory  
1200 molecule? Re-evaluating the evidence and the myth. *Journal of immunology (Baltimore, Md : 1950).*  
1201 2015;194(8):3542-8.
- 1202 29. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health  
1203 and disease. *Mol Immunol.* 2009;46(14):2753-66.
- 1204 30. Ezekowitz RA, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage  
1205 complement components. Role of receptors for complement in uptake of zymosan. *The Journal of*  
1206 *experimental medicine.* 1984;159(1):244-60.
- 1207 31. Goodrum KJ. Complement component C3 secretion by mouse macrophage-like cell lines. *J*  
1208 *Leukoc Biol.* 1987;41(4):295-301.
- 1209 32. Luo C, Chen M, Madden A, Xu H. Expression of complement components and regulators by  
1210 different subtypes of bone marrow-derived macrophages. *Inflammation.* 2012;35(4):1448-61.
- 1211 33. Galgiani JN, Yam P, Petz LD, Williams PL, Stevens DA. Complement activation by *Coccidioides*  
1212 *immitis*: in vitro and clinical studies. *Infect Immun.* 1980;28(3):944-9.

- 1213 34. Ratnoff WD, Pepple JM, Winkelstein JA. Activation of the alternative complement pathway by  
1214 *Histoplasma capsulatum*. *Infect Immun*. 1980;30(1):147-9.
- 1215 35. Kozel TR. Activation of the complement system by pathogenic fungi. *Clinical microbiology*  
1216 *reviews*. 1996;9(1):34-46.
- 1217 36. Zaragoza O, Taborda CP, Casadevall A. The efficacy of complement-mediated phagocytosis of  
1218 *Cryptococcus neoformans* is dependent on the location of C3 in the polysaccharide capsule and  
1219 involves both direct and indirect C3-mediated interactions. *European journal of immunology*.  
1220 2003;33(7):1957-67.
- 1221 37. Harpf V, Rambach G, Würzner R, Lass-Flörl C, Speth C. *Candida* and Complement: New Aspects  
1222 in an Old Battle. *Front Immunol*. 2020;11:1471.
- 1223 38. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is required for  
1224 beta-glucan recognition and control of fungal infection. *Nature immunology*. 2007;8(1):31-8.
- 1225 39. Tsoni SV, Kerrigan AM, Marakalala MJ, Srinivasan N, Duffield M, Taylor PR, et al. Complement  
1226 C3 plays an essential role in the control of opportunistic fungal infections. *Infect Immun*.  
1227 2009;77(9):3679-85.
- 1228 40. Shapiro S, Beenhouwer DO, Feldmesser M, Taborda C, Carroll MC, Casadevall A, et al.  
1229 Immunoglobulin G monoclonal antibodies to *Cryptococcus neoformans* protect mice deficient in  
1230 complement component C3. *Infect Immun*. 2002;70(5):2598-604.
- 1231 41. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and  
1232 immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune  
1233 phenomena. *Science (New York, NY)*. 1954;120(3112):279-85.
- 1234 42. Sun D, Zhang M, Liu G, Wu H, Zhu X, Zhou H, et al. Real-Time Imaging of Interactions of  
1235 Neutrophils with *Cryptococcus neoformans* Demonstrates a Crucial Role of Complement C5a-C5aR  
1236 Signaling. *Infect Immun*. 2016;84(1):216-29.
- 1237 43. Cheng SC, Sprong T, Joosten LA, van der Meer JW, Kullberg BJ, Hube B, et al. Complement plays  
1238 a central role in *Candida albicans*-induced cytokine production by human PBMCs. *European journal of*  
1239 *immunology*. 2012;42(4):993-1004.
- 1240 44. Kampmann M, Bassik MC, Weissman JS. Functional genomics platform for pooled screening and  
1241 generation of mammalian genetic interaction maps. *Nature Protocols*. 2014;9(8):1825-47.
- 1242 45. Jeng EE, Bhadkamkar V, Ibe NU, Gause H, Jiang L, Chan J, et al. Systematic Identification of Host  
1243 Cell Regulators of *Legionella pneumophila* Pathogenesis Using a Genome-wide CRISPR Screen. *Cell Host*  
1244 *Microbe*. 2019;26(4):551-63.e6.
- 1245 46. Park RJ, Wang T, Koundakjian D, Hultquist JF, Lamothe-Molina P, Monel B, et al. A genome-wide  
1246 CRISPR screen identifies a restricted set of HIV host dependency factors. *Nat Genet*. 2017;49(2):193-  
1247 203.
- 1248 47. Napier BA, Brubaker SW, Sweeney TE, Monette P, Rothmeier GH, Gertszvolf NA, et al.  
1249 Complement pathway amplifies caspase-11-dependent cell death and endotoxin-induced sepsis  
1250 severity. *The Journal of experimental medicine*. 2016;213(11):2365-82.
- 1251 48. Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, et al. Genome-scale  
1252 measurement of off-target activity using Cas9 toxicity in high-throughput screens. *Nature*  
1253 *communications*. 2017;8:15178.
- 1254 49. Worsham PL, Goldman WE. Selection and characterization of *ura5* mutants of *Histoplasma*  
1255 *capsulatum*. *Molecular & general genetics : MGG*. 1988;214(2):348-52.

- 1256 50. Morgens DW, Deans RM, Li A, Bassik MC. Systematic comparison of CRISPR/Cas9 and RNAi  
1257 screens for essential genes. *Nature biotechnology*. 2016;34(6):634-6.
- 1258 51. Haney MS, Bohlen CJ, Morgens DW, Ousey JA, Barkal AA, Tsui CK, et al. Identification of  
1259 phagocytosis regulators using magnetic genome-wide CRISPR screens. *Nat Genet*. 2018;50(12):1716-  
1260 27.
- 1261 52. Devreotes P, Horwitz AR. Signaling networks that regulate cell migration. *Cold Spring Harb*  
1262 *Perspect Biol*. 2015;7(8):a005959.
- 1263 53. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin  
1264 activation and platelet aggregation. *Nat Med*. 2008;14(3):325-30.
- 1265 54. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. *Nature reviews*  
1266 *Molecular cell biology*. 2013;14(3):133-9.
- 1267 55. Chitwood PJ, Hegde RS. The Role of EMC during Membrane Protein Biogenesis. *Trends Cell Biol*.  
1268 2019.
- 1269 56. Shurtleff MJ, Itzhak DN, Hussmann JA, Schirle Oakdale NT, Costa EA, Jonikas M, et al. The ER  
1270 membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane  
1271 proteins. *Elife*. 2018;7.
- 1272 57. Irannejad R, von Zastrow M. GPCR signaling along the endocytic pathway. *Current opinion in*  
1273 *cell biology*. 2014;27:109-16.
- 1274 58. Block H, Stadtmann A, Riad D, Rossaint J, Sohlbach C, Germena G, et al. Gnb isoforms control a  
1275 signaling pathway comprising Rac1, Plc $\beta$ 2, and Plc $\beta$ 3 leading to LFA-1 activation and neutrophil arrest  
1276 in vivo. *Blood*. 2016;127(3):314-24.
- 1277 59. Andreu N, Phelan J, de Sessions PF, Cliff JM, Clark TG, Hibberd ML. Primary macrophages and  
1278 J774 cells respond differently to infection with *Mycobacterium tuberculosis*. *Scientific reports*.  
1279 2017;7:42225.
- 1280 60. Haas PJ, van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation.  
1281 *Immunologic research*. 2007;37(3):161-75.
- 1282 61. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3a anaphylatoxin  
1283 receptor in the effector phase of asthma. *Nature*. 2000;406(6799):998-1001.
- 1284 62. Mueller-Ortiz SL, Hollmann TJ, Haviland DL, Wetsel RA. Ablation of the complement C3a  
1285 anaphylatoxin receptor causes enhanced killing of *Pseudomonas aeruginosa* in a mouse model of  
1286 pneumonia. *Am J Physiol Lung Cell Mol Physiol*. 2006;291(2):L157-65.
- 1287 63. Wu KY, Zhang T, Zhao GX, Ma N, Zhao SJ, Wang N, et al. The C3a/C3aR axis mediates anti-  
1288 inflammatory activity and protects against uropathogenic *E coli*-induced kidney injury in mice. *Kidney*  
1289 *Int*. 2019;96(3):612-27.
- 1290 64. Lian H, Litvinchuk A, Chiang AC, Aithmitti N, Jankowsky JL, Zheng H. Astrocyte-Microglia Cross  
1291 Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's  
1292 Disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*.  
1293 2016;36(2):577-89.
- 1294 65. Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR  
1295 Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy  
1296 Models and Alzheimer's Disease. *Neuron*. 2018;100(6):1337-53.e5.
- 1297 66. Zhang LY, Pan J, Mamtilahun M, Zhu Y, Wang L, Venkatesh A, et al. Microglia exacerbate white  
1298 matter injury via complement C3/C3aR pathway after hypoperfusion. *Theranostics*. 2020;10(1):74-90.

- 1299 67. Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, et al. Identification of a selective  
1300 nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity  
1301 in animal models. *Journal of immunology (Baltimore, Md : 1950)*. 2001;166(10):6341-8.
- 1302 68. Huang NN, Becker S, Boullaran C, Kamenyeva O, Vural A, Hwang IY, et al. Canonical and  
1303 noncanonical g-protein signaling helps coordinate actin dynamics to promote macrophage  
1304 phagocytosis of zymosan. *Molecular and cellular biology*. 2014;34(22):4186-99.
- 1305 69. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate  
1306 dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF)  
1307 activity. *J Immunol Methods*. 1988;115(1):61-9.
- 1308 70. Nilsson UR, Müller-Eberhard HJ. Deficiency of the fifth component of complement in mice with  
1309 an inherited complement defect. *The Journal of experimental medicine*. 1967;125(1):1-16.
- 1310 71. Zhang MX, Klein B. Activation, binding, and processing of complement component 3 (C3) by  
1311 *Blastomyces dermatitidis*. *Infect Immun*. 1997;65(5):1849-55.
- 1312 72. Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M, et al. Lifeact: a versatile  
1313 marker to visualize F-actin. *Nature methods*. 2008;5(7):605-7.
- 1314 73. Svensson CM, Medyukhina A, Belyaev I, Al-Zaben N, Figge MT. Untangling cell tracks:  
1315 Quantifying cell migration by time lapse image data analysis. *Cytometry Part A : the journal of the*  
1316 *International Society for Analytical Cytology*. 2018;93(3):357-70.
- 1317 74. Rougerie P, Miskolci V, Cox D. Generation of membrane structures during phagocytosis and  
1318 chemotaxis of macrophages: role and regulation of the actin cytoskeleton. *Immunological reviews*.  
1319 2013;256(1):222-39.
- 1320 75. Van Haastert PJ, Devreotes PN. Chemotaxis: signalling the way forward. *Nature reviews*  
1321 *Molecular cell biology*. 2004;5(8):626-34.
- 1322 76. Peracino B, Borleis J, Jin T, Westphal M, Schwartz JM, Wu L, et al. G protein beta subunit-null  
1323 mutants are impaired in phagocytosis and chemotaxis due to inappropriate regulation of the actin  
1324 cytoskeleton. *The Journal of cell biology*. 1998;141(7):1529-37.
- 1325 77. Pan M, Neilson MP, Grunfeld AM, Cruz P, Wen X, Insall RH, et al. A G-protein-coupled  
1326 chemoattractant receptor recognizes lipopolysaccharide for bacterial phagocytosis. *PLoS Biol*.  
1327 2018;16(5):e2005754.
- 1328 78. Freeman SA, Vega A, Riedl M, Collins RF, Ostrowski PP, Woods EC, et al. Transmembrane Pickets  
1329 Connect Cyto- and Pericellular Skeletons Forming Barriers to Receptor Engagement. *Cell*. 2018;172(1-  
1330 2):305-17.e10.
- 1331 79. Flannagan RS, Harrison RE, Yip CM, Jaqaman K, Grinstein S. Dynamic macrophage "probing" is  
1332 required for the efficient capture of phagocytic targets. *The Journal of cell biology*. 2010;191(6):1205-  
1333 18.
- 1334 80. Shen K, Sidik H, Talbot WS. The Rag-Ragulator Complex Regulates Lysosome Function and  
1335 Phagocytic Flux in Microglia. *Cell Rep*. 2016;14(3):547-59.
- 1336 81. Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant C, Grøfte M, et al. TRIP12 and UBR5  
1337 suppress spreading of chromatin ubiquitylation at damaged chromosomes. *Cell*. 2012;150(4):697-709.
- 1338 82. Cho JH, Kim SA, Seo YS, Park SG, Park BC, Kim JH, et al. The p90 ribosomal S6 kinase-UBR5  
1339 pathway controls Toll-like receptor signaling via miRNA-induced translational inhibition of tumor  
1340 necrosis factor receptor-associated factor 3. *The Journal of biological chemistry*. 2017;292(28):11804-  
1341 14.



- 1342 83. Surugiu R, Catalin B, Dumbrava D, Gresita A, Olaru DG, Hermann DM, et al. Intracortical  
1343 Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia  
1344 Reaction after Brain Injury. *Neural Plast.* 2019;2019:1071036.
- 1345 84. Sun D, Sun P, Li H, Zhang M, Liu G, Strickland AB, et al. Fungal dissemination is limited by liver  
1346 macrophage filtration of the blood. *Nature communications.* 2019;10(1):4566.
- 1347 85. Hwang LH, Mayfield JA, Rine J, Sil A. Histoplasma requires SID1, a member of an iron-regulated  
1348 siderophore gene cluster, for host colonization. *PLoS pathogens.* 2008;4(4):e1000044.
- 1349 86. Van Prooyen N, Henderson CA, Hocking Murray D, Sil A. CD103+ Conventional Dendritic Cells  
1350 Are Critical for TLR7/9-Dependent Host Defense against *Histoplasma capsulatum*, an Endemic Fungal  
1351 Pathogen of Humans. *PLoS pathogens.* 2016;12(7):e1005749.
- 1352 87. Worsham PL, Goldman WE. Quantitative plating of *Histoplasma capsulatum* without addition of  
1353 conditioned medium or siderophores. *Journal of medical and veterinary mycology : bi-monthly  
1354 publication of the International Society for Human and Animal Mycology.* 1988;26(3):137-43.
- 1355 88. Mead HL, Van Dyke MCC, Barker BM. Proper Care and Feeding of Coccidioides: A Laboratorian's  
1356 Guide to Cultivating the Dimorphic Stages of *C. immitis* and *C. posadasii*. *Curr Protoc Microbiol.*  
1357 2020;58(1):e113.
- 1358 89. Deans RM, Morgens DW, Okesli A, Pillay S, Horlbeck MA, Kampmann M, et al. Parallel shRNA  
1359 and CRISPR-Cas9 screens enable antiviral drug target identification. *Nat Chem Biol.* 2016;12(5):361-6.
- 1360 90. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome  
1361 editing by sequence trace decomposition. *Nucleic acids research.* 2014;42(22):e168.
- 1362 91. Bassik MC, Kampmann M, Lebbink RJ, Wang SY, Hein MY, Poser I, et al. A Systematic  
1363 Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility. *Cell.*  
1364 2013;152(4):909-22.
- 1365 92. Saldanha AJ. Java Treeview--extensible visualization of microarray data. *Bioinformatics.*  
1366 2004;20(17):3246-8.
- 1367 93. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of  
1368 enriched GO terms in ranked gene lists. *BMC bioinformatics.* 2009;10:48.
- 1369 94. Ollion J, Cochenec J, Loll F, Escudé C, Boudier T. TANGO: a generic tool for high-throughput 3D  
1370 image analysis for studying nuclear organization. *Bioinformatics.* 2013;29(14):1840-1.
- 1371 95. Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. *Methods Enzymol.*  
1372 2012;504:183-200.
- 1373 96. Isaac DT, Coady A, Van Prooyen N, Sil A. The 3-Hydroxy-Methylglutaryl Coenzyme A Lyase HCL1  
1374 Is Required for Macrophage Colonization by Human Fungal Pathogen *Histoplasma capsulatum*.  
1375 *Infection and Immunity.* 2013;81(2):411-20.
- 1376 97. Roy RM, Paes HC, Nanjappa SG, Sorkness R, Gasper D, Sterkel A, et al. Complement component  
1377 3C3 and C3a receptor are required in chitin-dependent allergic sensitization to *Aspergillus fumigatus*  
1378 but dispensable in chitin-induced innate allergic inflammation. *mBio.* 2013;4(2).
- 1379